There are no upcoming events.

“I do enjoy these meetings which are extremely informative and what I find most stimulating is the focus on future research. You are to be congratulated for organising these meetings and I am delighted to take part”

“What a crew! This sounds GREAT!

“I really enjoyed the discussions and the whole format of the day”

“It was the most exciting and thought-provoking meeting that I have ever attended”

“Thanks for allowing me to attend the Symposium on rectal cancer, which was really outstanding in underscoring the many needs we have in this field. I enjoyed it very much”

“Sounds fantastic”

“Inspiring talks and very interesting discussions, great meeting”

“Thank you for such an outstanding meeting.. One of the best – a very inspiring day!“

“I know how good these meetings are”

“Thank you for the symposium yesterday. I returned on the train last night with renewed enthusiasm and a desire to try and improve our service.“

“I am sure that it will be as entertaining and thought provoking as ever”

Colorectal Cancer Imaging Multidisciplinary Research Group

Clinical Trials

Our clinical trials are now sponsored by Imperial College London

Please click on the name of any of our trials below to find out more

Please click on the eligibility diagram to see how patients can be co-enrolled into our trials

Eligibility diagram

TRIGGER – a randomised trial looking at watch and wait for patients identified using mrTRG. The trial is a non-CTIMP therefore the preoperative treatment offered is according to local practice and not determined by the trial protocol (e.g. CRT, TNT)

COMET – a study evaluating tumour deposits vs lymph nodes in patients undergoing surgery to determine the relative importance of tumour deposits vs lymph nodes in predicting prognosis.

SERENADE – a study looking at earlier detection of liver metastases in patients with EMVI or tumour deposits using liver MRI.

IMPRESS – a randomised trial testing MRI staging for pelvic sigmoid cancer compared with CT to improve surgical outcomes.

Beyond TME Origins – a study evaluating the cause and treatment of pelvic recurrence following initial treatment of primary colon and rectal cancer in the pelvis.

ctDNA – a study to determine the relationship between ctDNA and EMVI/tumour deposits in patients undergoing primary colon or rectal cancer surgery

EVIDENCE – a tissue study evaluating whether distant metastases in colorectal cancer are related to EMVI and tumour deposits, not lymph nodes

DRIVEN – a retrospective analysis of pre-operative prognostic biomarkers in resected right compared with left colon cancer, and the influence of operative approach on survival

PRESERVE – a study to determine if we can successfully introduce accurate MRI staging of early rectal cancer into MDTs in 20 NHS Trusts

MERCURY 3 – a study to determine that a different staging system of mrTDV will improve the care and survival rates of patients with rectal cancer compared with the current practice of using TNM.

TRIALS CLOSED TO RECRUITMENT

6 vs 12

Deferral of Surgery

MARVEL

MERCURY II

SOPRANO

Workshops

Rectal MRI Virtual Handson Workshops

Open to recruitment

Please click on the trial you wish to know more about

COMET

Presentations

Beyond TME – why the need for pelvic exenteration

C T colon staging and importance of proforma reporting

Detection and description of peritoneal metastases by CT

Developments in Colorectal Cancer

Early Rectal Cancer

Management of Advanced Rectal Cancer

MRI detection of EMVI in rectal cancer

MRI standards for Rectal Cancer Staging

MRI Techniques for Rectal Cancer

Peritoneal spread risk in gastric, pancreatic and colon cancers

Reporting Proforma Templates for Colon and Rectal cancer

Staging colon and sigmoid cancer by CT and MRI

Cart

Co-Chairs

Prof Gina Brown was awarded her Chair in Gastrointestinal Imaging at Imperial College London in 2015 and is also Consultant Radiologist for Imperial College NHS Foundation Trust.

Her research in colorectal cancer staging has set the national and global benchmarks for imaging assessment of colon and rectal cancer patients before and during treatment. These improved staging methods have resulted MRI based strategies being incorporated into several guidelines such as peer review measures, UK NICE and guidelines.

Mr Arnold Goede has been a Consultant Surgeon in Buckinghamshire Healthcare NHS Trust since 2011. His expertise includes advanced endoscopic procedures such as colonoscopy and polypectomy

Recently he has started Robotic Surgery in the NHS for patients with bowel and rectal cancer undergoing major surgery, and also Transanal Minimally Invasive Surgery using the TAMIS platform, to remove large benign polyps or early rectal cancers in selected patients.

Invited Guest Faculty

Prof James East is one of Europe’s leading colonoscopists. He works as a Consultant Gastroenterologist and Endoscopist, and is an Associate Professor, based at the Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford and Mayo Clinic Healthcare London

For the last decade he has been the Clinical Lead for Endoscopy at the John Radcliffe and Director of Bowel Cancer Screening Oxfordshire

Prof Iris Nagtegaal is Professor of Gastrointestinal Pathology since 2013 and theme leader of the research theme: Tumours of the digestive tract. She is gastrointestinal pathologist in the Radboudumc and expert pathologist of the National Bowel Cancer Screening Program.

Her main research interest focuses on personalized pathology of colorectal cancer: improving patients prognosis by providing evidence based diagnosis and basis for treatment.

Mr Roel Hompes is an honorary fellow of the American Society of Colon and Rectal Surgeons (ASCRS). He specializes in minimally invasive surgery (laparoscopy and TAMIS), and the management of colorectal cancer.

He has a strong interest in the management of early rectal cancer and transanal approaches for rectal cancer. The lower GI departement of the AUMC is one of the leading centres world wide in this field.

Mr Stephen Boyce trained in Edinburgh, and undertook specialist minimally-invasive colorectal surgery Fellowships in Sydney and Brisbane.

His predominant interest is in minimally-invasive techniques for treating patients with rectal cancer, including robotic surgery.

He is a Regional Surgical Advisor for the RCSEd.

Mr Francesco Di Fabio is involved in the management of patients with rectal cancer and he runs a dedicated Rectal Cancer Clinic. His clinical expertise also includes management of patients with significant colorectal polyps.

In 2018 he set up a dedicated Significant Polyp and Early Colorectal Cancer (SPECC) Multidisciplinary Team Meeting to support clinicians and patients in the decision-making process.

Mr Amyn Haji was appointed as a Consultant in Colorectal and Laparoscopic Surgery at King’s College Hospital in 2011

His research and clinical interests are in utilization of high frequency colonoscopy ultrasound in the staging of colorectal polyps and cancer. He has developed a practice of endoscopic mucosal resection and endoscopic submucosal dissection in the treatment of colorectal polyps. He uses advanced endoscopic techniques and is an expert in interventional endoscopy.

Dr Adriana Martinez trained in Medicine at ‘Universidad CES’ in Medellin, Colombia and pursued her postgraduate training in the United Kingdom.

She has been a Consultant Gastro-intestinal Pathologist and Dermatopathologist at Northwick Park and St Mark’s Hospitals since 2007. She is the Clinical Lead for Histopathology.

Dr Kevin Monahan is Consultant Gastroenterologist at the Family Cancer Clinic & the Wolfson Unit for Endoscopy and Co Director of The St Mark’s Centre for Familial Intestinal Cancer

He undertook his PhD at Cancer Research UK and St Mark’s Hospital, and has an interest in prevention and early detection of cancer, particularly in the field of endoscopy, colorectal, pancreatic and other gastrointestinal cancers.

Dr Noriko Suzuki has been a member of the staff at St Marks since 1998 and an honorary consultant specialist endoscopist since 2004.

She trained in medicine at Osaka City University and completed specialist training in Japan. Her interests include the prevention, diagnosis and management of intestinal diseases utilising endoscopy. She has a particular interest in complex therapeutic endoscopy such as endoscopic submucosal dissection.

Rachel is a Registrar in General and Colorectal Surgery in Wessex Deanery, and is currently undertaking a Clinical Research Fellowship at Buckinghamshire Healthcare NHS Trust with Prof Gina Brown at Imperial College London.

She has research and clinical interests in the management of Early Rectal Cancer and is the PRESERVE Trial Research Fellow.

Checkout

Publications

2025

Kuzu, M. A., Benlice, C., Parvaiz, A., Gorgun, E., Bertelsen, C. A., Wexner, S., Brown, G. . . Bordeianou, L. G. (n.d.). Standardizing the Definition of Each Colon Cancer Segment: Delphi Consensus on Clinical Decision-Making for Oncologic Outcomes. Diseases of the Colon & Rectum. doi:10.1097/dcr.0000000000003739

Wale, A., Harris, H., & Brown, G. (2025). Diagnostic Certainty in Characterizing Liver Lesions in Rectal Cancer: Abbreviated Liver MRI versus CT. Annals of Surgical Oncology, 32(4), 2435-2445. doi:10.1245/s10434-024-16468-2

Wale, A., Harris, H., & Brown, G. (n.d.). ASO Visual Abstract: Diagnostic Certainty in Characterizing Liver Lesions in Rectal Cancer: Abbreviated Liver MRI Versus CT. ANNALS OF SURGICAL ONCOLOGY, 2 pages. doi:10.1245/s10434-024-16601-1

Wale, A., & Brown, G. (2025). ASO Author Reflections: Diagnostic Certainty in Characterizing Liver Lesions in Rectal Cancer: Abbreviated Liver MRI Versus CT. Annals of Surgical Oncology, 32(4), 2481-2482. doi:10.1245/s10434-024-16605-x

Bregni, G., Adams, R., Bale, R., Bali, M. A., Bargellini, I., Blomqvist, L., Brown, G. . . Sclafani, F. (2025). EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases. Cancer Treatment Reviews, 136, 102926. doi:10.1016/j.ctrv.2025.102926

Oguz Erdogan, A. S., Brouwer, N. P. M., Angerilli, V., Rutgers, N., Brown, G., Simmer, F., & Nagtegaal, I. D. (2025). The number of potential gateways determines prognostic value of tumour deposits in colon cancer. Pathology. doi:10.1016/j.pathol.2024.12.635

Wale, A., Bernier, L., Tait, D., Rao, S., & Brown, G. (2025). Simple imaging biomarker predicts survival in anal squamous cell cancer treated with curative intent: a UK cohort study. Clinical Radiology, 80, 106718. doi:10.1016/j.crad.2024.10.001

Nougaret, S., Gormly, K., Lambregts, D. M. J., Reinhold, C., Goh, V., Korngold, E., . . . Brown, G. (2025). MRI of the Rectum: A Decade into DISTANCE, Moving to DISTANCED. Radiology, 314(1). doi:10.1148/radiol.232838

Brown, G., Camilleri, G., & Lal, N. (2025). Lymph node imaging in colorectal cancer. In Colorectal Imaging (pp. 201-224). Elsevier. doi:10.1016/b978-0-443-29048-0.00011-2

2024

Brouwer, N. P. M., Oguz Erdogan, A. S., van Vliet, S., Rutgers, N., Knijn, N., van Lijnschoten, G., Brown, G. . . Nagtegaal, I. D. (2024). Unraveling the routes to distant metastases in colorectal cancer: tumor deposits and lymph node metastases as the gateway. Cancer Communications, 44(10), 1209-1213. doi:10.1002/cac2.12598

Rokan, Z., Wale, A., Day, N., Kontovounisios, C., Moran, B., & Brown, G. (2024). Pelvic exenteration for locally advanced rectal cancer and associated outcomes in England between 1995 and 2016: Analysis of a national database. COLORECTAL DISEASE, 26(10), 1805-1814. doi:10.1111/codi.17137

Scott, A. J., Kennedy, E. B., Berlin, J., Brown, G., Chalabi, M., Cho, M. T., . . . Gholami, S. (2024). Management of Locally Advanced Rectal Cancer: ASCO Guideline. JOURNAL OF CLINICAL ONCOLOGY, 42(28), 24 pages. doi:10.1200/JCO.24.01160

Fadel, M. G., Ahmed, M., Shaw, A., Fehervari, M., Kontovounisios, C., & Brown, G. (2024). Oncological outcomes of local excision versus radical surgery for early rectal cancer in the context of staging and surveillance: a systematic review and meta-analysis. Cancer Treatment Reviews, 128. doi:10.1016/j.ctrv.2024.102753

2023

Hak, C. C. W., Balyasnikova, S., Withey, S., Tait, D., Brown, G., & Chong, I. (2023). Radiological Biomarkers in MRI directed Rectal Cancer Radiotherapy Volume Delineation. CANCERS, 15(21), 12 pages. doi:10.3390/cancers15215176

Hodges, N., Battersby, N., Rao, S., & Brown, G. (n.d.). Relationship Between Baseline Rectal Tumor Length and Magnetic Resonance Tumor Regression Grade Response to Chemoradiotherapy: A Subanalysis of the TRIGGER Feasibility Study. ANNALS OF SURGICAL ONCOLOGY, 7 pages. doi:10.1245/s10434-022-11914-5

Hodges, N., Battersby, N., Rao, S., & Brown, G. (n.d.). ASO Visual Abstract: The Relationship Between Baseline Rectal Tumour Length and Magnetic Resonance Tumour Regression Grade (mrTRG) Response to Chemoradiotherapy-A Subanalysis of the Trigger Feasibility Study. ANNALS OF SURGICAL ONCOLOGY, 1 page. doi:10.1245/s10434-022-11961-y

Stelzner, S., Heinze, T., Heimke, M., Gockel, I., Kittner, T., Brown, G., . . . Wedel, T. (2023). Beyond Total Mesorectal Excision Compartment-based Anatomy of the Pelvis Revisited for Exenterative Pelvic Surgery. ANNALS OF SURGERY, 278(1), E58-E67. doi:10.1097/SLA.0000000000005715

Hodges, N., Duxbury, O., Corr, A., Cho, S. H., Miskovic, D., & Brown, G. (2023). Inter- rater agreement between radiologists using the novel CT- TDV (T3c+; tumour deposits; EMVI) system in patients with potentially curable right colon cancer. BRITISH JOURNAL OF RADIOLOGY, 96(1146), 6 pages. doi:10.1259/bjr.20220682

Burns, E. M., Quyn, A., & Lexicon Collaboration of UKPEN and the ACPGBI Advanced Cancer subcommittee. (2023). The ‘Pelvic exenteration lexicon’: Creating a common language for complex pelvic cancer surgery.. Colorectal Dis, 25(5), 888-896. doi:10.1111/codi.16476

Burghgraef, T. A., Hol, J. C., Rutgers, M. L., Brown, G., Hompes, R., Sietses, C., & Consten, E. C. J. (2023). Implications of the new MRI-based rectum definition according to the sigmoid take-off: multicentre cohort study. BJS OPEN, 7(2), 8 pages. doi:10.1093/bjsopen/zrad018

2022

Fadel, M. G., Ahmed, M., Malietzis, G., Pellino, G., Rasheed, S., Brown, G., . . . Kontovounisios, C. (2022). Oncological outcomes of multimodality treatment for patients undergoing surgery for locally recurrent rectal cancer: A systematic review. CANCER TREATMENT REVIEWS, 109, 10 pages. doi:10.1016/j.ctrv.2022.102419

Hodges, N., Battersby, N., Rao, S., Brown, G., & TRIGGER Study Group. (2022). Relationship Between Baseline Rectal Tumor Length and Magnetic Resonance Tumor Regression Grade Response to Chemoradiotherapy: A Subanalysis of the TRIGGER Feasibility Study.. Ann Surg Oncol. doi:10.1245/s10434-022-11914-5

Rokan, Z., Simillis, C., Kontovounisios, C., Moran, B., Tekkis, P., & Brown, G. (2022). Locally Recurrent Rectal Cancer According to a Standardized MRI Classification System: A Systematic Review of the Literature. JOURNAL OF CLINICAL MEDICINE, 11(12), 16 pages. doi:10.3390/jcm11123511

Lord, A. C., Corr, A., Chandramohan, A., Hodges, N., Pring, E., Airo-Farulla, C., . . . Brown, G. (2022). Assessment of the 2020 NICE criteria for preoperative radiotherapy in patients with rectal cancer treated by surgery alone in comparison with proven MRI prognostic factors: a retrospective cohort study.. Lancet Oncol, 23(6), 793-801. doi:10.1016/S1470-2045(22)00214-5

Hodges, N., Mackenzie, H., D’Souza, N., Brown, G., & Miskovic, D. (2022). Survival outcomes for right-versus left-sided colon cancer and rectal cancer in England: A propensity-score matched population-based cohort study. EJSO, 48(4), 841-849. doi:10.1016/j.ejso.2021.10.007

Fernandes, M. C., Gollub, M. J., & Brown, G. (2022). The importance of MRI for rectal cancer evaluation.. Surg Oncol, 101739. doi:10.1016/j.suronc.2022.101739

Robb, H., Scrimgeour, G., Boshier, P., Przedlacka, A., Balyasnikova, S., Brown, G., . . . Kontovounisios, C. (2022). The current and possible future role of 3D modelling within oesophagogastric surgery: a scoping review. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 14 pages. doi:10.1007/s00464-022-09176-z

2021

Huddy, J. R., Rasheed, S., Brown, G., & Tilney, H. S. (2021). Comment on “Cancer Surgery During COVID-19: How We Move Forward”. ANNALS OF SURGERY, 274(6), E827-E828. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000718532600217&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Robb, H. D., Scrimgeour, G., Boshier, P. R., Balyasnikova, S., Brown, G., Bello, F., & Kontovounisios, C. (2021). Current and possible future role of 3D modelling within oesophagogastric surgery: a scoping review protocol. BMJ OPEN, 11(10), 4 pages. doi:10.1136/bmjopen-2020-045546

Brouwer, N. P. M., Lord, A. C., Terlizzo, M., Bateman, A. C., West, N. P., Goldin, R., . . . Brown, G. (2021). Interobserver variation in the classification of tumor deposits in rectal cancer-is the use of histopathological characteristics the way to go?. VIRCHOWS ARCHIV, 479(6), 1111-1118. doi:10.1007/s00428-021-03197-0

Tan, J. J., V. Carten, R., Babiker, A., Abulafi, M., Lord, A. C., & Brown, G. (2021). Prognostic Importance of MRI-Detected Extramural Venous Invasion in Rectal Cancer: A Literature Review and Systematic Meta-Analysis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 111(2), 385-394. doi:10.1016/j.ijrobp.2021.05.136

Rao, S., Guren, M. G., Khan, K., Brown, G., Renehan, A. G., Steigen, S. E., . . . Arnold, D. (2021). Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 32(9), 1087-1100. doi:10.1016/j.annonc.2021.06.015

Day, N., D’Souza, N., Shaw, A., Lord, A., Abulafi, M., Moran, B., . . . Brown, G. (2021). Local recurrence in sigmoid cancer is a hidden problem, could CT prognostic factors be of value in their prevention? A multi-centre study of 414 patients. EJSO, 47(8), 2093-2099. doi:10.1016/j.ejso.2021.03.254

Lord, A., Brown, G., Abulafi, M., Bateman, A., Frankel, W., Goldin, R., . . . Nagtegaal, I. (2021). Histopathological diagnosis of tumour deposits in colorectal cancer: a Delphi consensus study. HISTOPATHOLOGY, 79(2), 168-175. doi:10.1111/his.14344

Rokan, Z., Simillis, C., Kontovounisios, C., Moran, B. J., Tekkis, P., & Brown, G. (2021). Systematic review of classification systems for locally recurrent rectal cancer. BJS OPEN, 5(3), 14 pages. doi:10.1093/bjsopen/zrab024

2020

Huddy, J. R., Tilney, H. S., Rasheed, S., Rasheed, S., Tilney, H. S., & Brown, G. (2020). Comment on “Cancer Surgery During COVID-19: How we Move Forward”.. Ann Surg. doi:10.1097/SLA.0000000000004544

Lord, A. C., DʼSouza, N., Shaw, A., Rokan, Z., Moran, B., Abulafi, M., . . . Brown, G. (2020). MRI-Diagnosed Tumour Deposits and EMVI Status Have Superior Prognostic Accuracy to Current Clinical TNM Staging in Rectal Cancer.. Ann Surg. doi:10.1097/SLA.0000000000004499

Huddy, J. R., Rasheed, S., Brown, G., & Tilney, H. S. (2020). Letter to the Editor RE: “COVID-19 Impact on Colorectal Daily Practice-How Long Will It Take to Catch Up?”. JOURNAL OF GASTROINTESTINAL SURGERY, 24(11), 2696-2697. doi:10.1007/s11605-020-04795-0

D’Souza, N., Lord, A., Shaw, A., Patel, A., Balyasnikova, S., Tudyka, V., . . . Brown, G. (2020). The sigmoid take-off: An anatomical imaging definition of the rectum validated on specimen analysis. EJSO, 46(9), 1668-1672. doi:10.1016/j.ejso.2020.01.008

Keller, D. S., Berho, M., Brown, G., Hull, T., Moeslein, G., & Wexner, S. D. (2020). A narrative celebrating the recent contributions of women to colorectal surgery. SURGERY, 168(3), 355-362. doi:10.1016/j.surg.2020.06.024

Lord, A. C., Knijn, N., Brown, G., & Nagtegaal, I. D. (2020). Pathways of spread in rectal cancer: a reappraisal of the true routes to distant metastatic disease. EUROPEAN JOURNAL OF CANCER, 128, 1-6. doi:10.1016/j.ejca.2019.12.025

Glynne-Jones, R., Wyrwicz, L., Tiret, E., Brown, G., Rodel, C., Cervantes, A., & Arnold, D. (2017). Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 28, 22-40. doi:10.1093/annonc/mdx224

Khakoo, S., Carter, P. D., Brown, G., Valeri, N., Picchia, S., Bali, M. A., . . . Cunningham, D. (2020). MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. CLINICAL CANCER RESEARCH, 26(1), 183-192. doi:10.1158/1078-0432.CCR-19-1996

Lord, A. C., Moran, B., Abulafi, M., Rasheed, S., Nagtegaal, I. D., Terlizzo, M., & Brown, G. (2020). Can extranodal tumour deposits be diagnosed on MRI? Protocol for a multicentre clinical trial (the COMET trial). BMJ OPEN, 10(10), 7 pages. doi:10.1136/bmjopen-2019-033395

Sclafani, F., Wilson, S. H., Cunningham, D., De Castro, D. G., Kalaitzaki, E., Begum, R., . . . Chau, I. (2020). Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. INTERNATIONAL JOURNAL OF CANCER, 146(1), 94-102. doi:10.1002/ijc.32507

2019

D’Souza, N., Babberich, M. P. M. D. N. T., d’Hoore, A., Tiret, E., Xynos, E., Beets-Tan, R. G. H., . . . Brown, G. (2019). Definition of the Rectum An International, Expert-based Delphi Consensus. ANNALS OF SURGERY, 270(6), 955-959. doi:10.1097/SLA.0000000000003251

D’Souza, N., Shaw, A., Lord, A., Balyasnikova, S., Abulafi, M., Tekkis, P., & Brown, G. (2019). Assessment of a Staging System for Sigmoid Colon Cancer Based on Tumor Deposits and Extramural Venous Invasion on Computed Tomography. JAMA NETWORK OPEN, 2(12), 11 pages. doi:10.1001/jamanetworkopen.2019.16987

Lord, A. C., Martinez, C. G., D’Souza, N., Pucher, P. H., Brown, G., & Nagtegaal, I. D. (2019). The significance of tumour deposits in rectal cancer after neoadjuvant therapy: a systematic review and meta-analysis. EUROPEAN JOURNAL OF CANCER, 122, 1-8. doi:10.1016/j.ejca.2019.08.020

Davidson, M., Aronson, L. I., Howard-Reeves, J., Bryant, H., Cutts, R. J., Hulkki-Wilson, S., . . . Chong, I. Y. (2019). Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme. EUROPEAN JOURNAL OF CANCER, 122, 12-21. doi:10.1016/j.ejca.2019.09.003

D’Souza, N., Lord, A. C., Shaw, A., Patel, A., Balyasnikova, S., Tudyka, V., . . . Brown, G. (2019). Ex vivo specimen MRI and pathology confirm a rectosigmoid mesenteric waist at the junction of the mesorectum and mesocolon. COLORECTAL DISEASE, 22(2), 212-218. doi:10.1111/codi.14856

Lord, A., D’Souza, N., Shaw, A., Day, N., & Brown, G. (2019). The Current Status of Nodal Staging in Rectal Cancer. CURRENT COLORECTAL CANCER REPORTS, 15(5), 143-148. doi:10.1007/s11888-019-00441-3

Vallance, A. E., Harji, D., & Fearnhead, N. S. (2019). Making an IMPACT: A priority setting consultation exercise to improve outcomes in patients with locally advanced, recurrent and metastatic colorectal cancer. EJSO, 45(9), 1567-1574. doi:10.1016/j.ejso.2019.04.005

Kennedy, E. D., Simunovic, M., Jhaveri, K., Kirsch, R., Brierley, J., Drolet, S., . . . Baxter, N. N. (2019). Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With “Good Prognosis” Rectal Cancer Eligible for Primary Surgery The Phase 2 Nonrandomized QuickSilver Clinical Trial. JAMA ONCOLOGY, 5(7), 961-966. doi:10.1001/jamaoncol.2019.0186

Keller, D. S., & Brown, G. (2019). Invited editorial re: “Response assessment after (chemo) radiotherapy for rectal cancer: Why are we missing complete responses with MRI and endoscopy?”. EJSO, 45(6), 929-930. doi:10.1016/j.ejso.2018.12.013

West, M. A., Astin, R., Moyses, H. E., Cave, J., White, D., Levett, D. Z. H., . . . Jack, S. (2019). Exercise prehabilitation may lead to augmented tumor regression following neoadjuvant chemoradiotherapy in locally advanced rectal cancer. ACTA ONCOLOGICA, 58(5), 588-595. doi:10.1080/0284186X.2019.1566775

Pooni, A., Al-Sukhni, E., Milot, L., Fruitman, M., Victor, J. C., Schmocker, S., . . . Kennedy, E. (2019). Selection of Patients With Rectal Cancer for Preoperative Chemoradiotherapy: Are T Category and Nodal Status All That Matters?. DISEASES OF THE COLON & RECTUM, 62(4), 447-453. doi:10.1097/DCR.0000000000001229

D’Souza, N., Lord, A., Shaw, A., Abulafi, M., Kontovounisios, C., Sjovall, A., . . . Brown, G. (2019). Meta-analysis of oncological outcomes of sigmoid cancers: A hidden epidemic of R1 “palliative” resections. EJSO, 45(4), 489-497. doi:10.1016/j.ejso.2018.09.028

Balyasnikova, S., & Brown, G. (2019). The MRI assessment of SPECC (significant polyps and early colorectal cancer) lesions.. Colorectal Dis, 21 Suppl 1, 19-22. doi:10.1111/codi.14526

West, M. A., Astin, R., Moyses, H. E., Cave, J., White, D., Levett, D. Z. H., . . . Jack, S. (2019). Exercise prehabilitation may lead to augmented tumor regression following neoadjuvant chemoradiotherapy in locally advanced rectal cancer.. Acta Oncol, 1-8. doi:10.1080/0284186X.2019.1566775

2018

Sclafani, F., Kalaitzaki, E., Cunningham, D., Tait, D., Brown, G., & Chau, I. (2018). Neoadjuvant rectal score: run with the hare and hunt with the hounds. ANNALS OF ONCOLOGY, 29(11), 2261-2262. doi:10.1093/annonc/mdy403

Siddiqui, M. R. S., Simillis, C., Bhoday, J., Battersby, N. J., Mok, J., Rasheed, S., . . . Brown, G. (2018). A meta-analysis assessing the survival implications of subclassifying T3 rectal tumours. EUROPEAN JOURNAL OF CANCER, 104, 47-61. doi:10.1016/j.ejca.2018.07.131

D’Souza, N., Lord, A., Shaw, A., Abulafi, M., Kontovounisios, C., Sjövall, A., . . . Brown, G. (2018). Meta-analysis of oncological outcomes of sigmoid cancers: A hidden epidemic of R1 “palliative” resections.. Eur J Surg Oncol. doi:10.1016/j.ejso.2018.09.028

Patel, A., Rockall, A., Guthrie, A., Gleeson, F., Worthy, S., Grubnic, S., . . . Brown, G. (2018). Can the completeness of radiological cancer staging reports be improved using proforma reporting? A prospective multicentre non-blinded interventional study across 21 centres in the UK. BMJ OPEN, 8(10), 11 pages. doi:10.1136/bmjopen-2017-018499

Glynne-Jones, R., Wyrwicz, L., Tiret, E., Brown, G., Rödel, C., Cervantes, A., . . . ESMO Guidelines Committee. (2018). Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.. Ann Oncol, 29(Supplement_4), iv263. doi:10.1093/annonc/mdy161

Davidson, M., Nankivell, M., Cunningham, D., Starling, N., Koh, D. -M., Brown, G., . . . Riddell, A. (2018). Magnetic resonance imaging in oesophageal (oes) cancer: Results from the STO3 MRI substudy. In ANNALS OF ONCOLOGY Vol. 29 (pp. 1 page). Munich, GERMANY: OXFORD UNIV PRESS. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459277301217&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Khakoo, S., Carter, P., Valeri, N., Shaikh, R., Jones, T., Begum, R., . . . Cunningham, D. (2018). Circulating tumour DNA (ctDNA) as a tool to assess response and guide therapy adaptation in rectal cancer. In ANNALS OF ONCOLOGY Vol. 29 (pp. 661). Munich, GERMANY: OXFORD UNIV PRESS. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459277304231&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Lord, A. C., D’Souza, N., Pucher, P. H., Moran, B. J., Abulafi, A. M., Wotherspoon, A., . . . Brown, G. (2018). Author response to comment on ‘significance of extranodal tumour deposits in colorectal cancer: A systematic review and meta-analysis’. EUROPEAN JOURNAL OF CANCER, 105, 129-130. doi:10.1016/j.ejca.2018.08.018

D’Souza, N., Balyasnikova, S., Tudyka, V., Lord, A., Shaw, A., Abulafi, M., . . . Brown, G. (2018). Variation in landmarks for the rectum: an MRI study. COLORECTAL DISEASE, 20(10), O304-O309. doi:10.1111/codi.14398

D’Souza, N., Babberich, M. P. M. D. N. T., Lord, A., Shaw, A., Abulafi, M., Tekkis, P., . . . Brown, G. (2018). The rectosigmoid problem. SURGICAL ONCOLOGY-OXFORD, 27(3), 521-525. doi:10.1016/j.suronc.2018.06.005

Chand, M., Keller, D. S., Mirnezami, R., Bullock, M., Bhangu, A., Moran, B., . . . Berho, M. (2018). Novel biomarkers for patient stratification in colorectal cancer: A review of definitions, emerging concepts, and data. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 10(7), 145-158. doi:10.4251/wjgo.v10.i7.145

Tekkis, P., Tait, D., Cunningham, D., & Brown, G. (2018). Is organ preservation in rectal cancer ready for prime time?. LANCET, 391(10139), 2480-2482. doi:10.1016/S0140-6736(18)31324-2

Sao Juliao, G. P., Ortega, C. D., Vailati, B. B., Coutinho, F. A. B., Rossi, G., Habr-Gama, A., . . . Perez, R. O. (2018). The Estimate of the Impact of Coccyx Resection in Surgical Field Exposure During Abdominal Perineal Resection Using Preoperative High-Resolution Magnetic Resonance. WORLD JOURNAL OF SURGERY, 42(11), 3765-3770. doi:10.1007/s00268-018-4683-x

Bhoday, J., Glimelius, B., Tait, D., Glynne-Jones, R., Adams, R., & Brown, G. (2018). Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?. COLORECTAL DISEASE, 20, 97-99. doi:10.1111/codi.14088

Battersby, N. J., Perez, R. O., Baxter, N., Moran, B., & Brown, G. (2018). Session 4: Trying to augment response with chemotherapy: a triumph of hope over experience?. COLORECTAL DISEASE, 20, 100-102. doi:10.1111/codi.14089

Dattani, M., Marijnen, C., Moran, B., Tait, D., Cunningham, C., Rodriguez-Bigas, M., & Brown, G. (2018). Session 4: Shaping radiotherapy for rectal cancer: should this be personalized?. COLORECTAL DISEASE, 20, 92-96. doi:10.1111/codi.14087

Read, J., Tekkis, P., Rullier, E., Nicholls, J., Mortensen, N., Marks, J., . . . Brown, G. (2018). Session 3: Many ways to organ preserve the rectum but which is correct?. COLORECTAL DISEASE, 20, 82-87. doi:10.1111/codi.14085

Patel, A., Chang, G., Wale, A., Chong, I., Rutten, H., Nicholls, J., . . . Brown, G. (2018). Session 3: Intra-operative radiotherapy – creating new surgical boundaries. COLORECTAL DISEASE, 20, 65-75. doi:10.1111/codi.14083

Balyasnikova, S., Vuong, T., Wale, A., Chong, I., Rutten, H., & Brown, G. (2018). Session 3: Boosting primary and recurrent rectal cancer: how far can we push the radiotherapy envelope?. COLORECTAL DISEASE, 20, 88-91. doi:10.1111/codi.14086

Patel, U. B., Blomqvist, L., Chau, I., Nicholls, J., & Brown, G. (2018). Session 3: Beyond TME and radiotherapy MRI evaluation of rectal cancer treatment response. COLORECTAL DISEASE, 20, 76-81. doi:10.1111/codi.14084

Patel, A., Holm, T., Wale, A., Rutten, H., Nicholls, J., Hawkins, M., . . . Brown, G. (2018). Session 3: Beyond the boundaries of Total Mesorectal Excision – where surgeons fear to tread. COLORECTAL DISEASE, 20, 61-64. doi:10.1111/codi.14082

Siddiqui, M., Nagtegaal, I., Santiago, I., Knijn, N., Berho, M., Mirnezami, A., . . . Brown, G. (2018). Session 2: What causes liver metastases – lymph nodes or is it something else?. COLORECTAL DISEASE, 20, 39-42. doi:10.1111/codi.14077

Wale, A., Van Cutsem, E., Rao, S., Cunningham, D., & Brown, G. (2018). Session 2: Synchronous metastatic disease-liver first or primary first? The oncologist decides. COLORECTAL DISEASE, 20, 52-55. doi:10.1111/codi.14080

Siddiqui, M., Chand, M., Eng, C., Mehdizadeh, A., Mirnezami, A., & Brown, G. (2018). Session 2: Mutational discordance: the big challenge in personalized treatments – any solutions?. COLORECTAL DISEASE, 20, 49-51. doi:10.1111/codi.14079

Balyasnikova, S., Haboubi, N., Wale, A., Santiago, I., Morgan, M., Cunningham, D., . . . Brown, G. (2018). Session 2: Extramural vascular invasion and extranodal deposits: should they be treated the same?. COLORECTAL DISEASE, 20, 43-48. doi:10.1111/codi.14078

Patel, U. B., Cervantes, A., Fernandez-Martos, C., Sclafani, F., Cunningham, D., Nilsson, P., & Brown, G. (2018). Session 2: Are we ready for primary chemotherapy in rectal cancer: who, when, why?. COLORECTAL DISEASE, 20, 56-60. doi:10.1111/codi.14081

Bhoday, J., Martling, A., Strassburg, J., & Brown, G. (2018). Session 1: The surgeon as a prognostic factor in colon and rectal cancer?. COLORECTAL DISEASE, 20, 36-38. doi:10.1111/codi.14076

Wale, A., Wexner, S. D., Saur, N. M., Massarotti, H., Laurberg, S., Kennedy, E., . . . Brown, G. (2018). Session 1: The evolution and development of the multidisciplinary team approach: USA, European and UK experiences – what can we do better?. COLORECTAL DISEASE, 20, 17-27. doi:10.1111/codi.14073

Tudyka, V., Madoff, R., Wale, A., Laurberg, S., Yano, H., & Brown, G. (2018). Session 1: Colon cancer-10years behind the rectum. COLORECTAL DISEASE, 20, 28-33. doi:10.1111/codi.14074

Brown, G. (2018). Proceedings of the Future Horizons International Experts Meeting in Colorectal Cancer Held in London on 25th June 2015. Edited by: Dr Anita Wale and Prof Gina Brown. COLORECTAL DISEASE, 20, 5-7. doi:10.1111/codi.14068

Bernier, L., Balyasnikova, S., Tait, D., & Brown, G. (2018). Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer. CURRENT COLORECTAL CANCER REPORTS, 14(2), 37-55. doi:10.1007/s11888-018-0398-5

Sclafani, F., Chau, I., Cunningham, D., Hahne, J. C., Vlachogiannis, G., Eltahir, Z., . . . Valeri, N. (2018). KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. SCIENTIFIC REPORTS, 8, 9 pages. doi:10.1038/s41598-018-19212-5

Chand, M., & Brown, G. (2018). Important imaging considerations in the pre-operative assessment of rectal cancer (Reprinted from Seminars in Colon and Rectal Surgery, vol 25, pg 6-12, 2014). SEMINARS IN COLON AND RECTAL SURGERY, 29(4), 199-205. doi:10.1053/j.scrs.2018.11.008

Lawler, M., Alsina, D., Adams, R. A., Anderson, A. S., Brown, G., Fearnhead, N. S., . . . Tomlinson, I. (2018). Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. GUT, 67(1), 179-193. doi:10.1136/gutjnl-2017-315333

Siddiqui, M., Balyansikova, S., Nagtegaal, I., West, N., Murray, G., Bosch, S., . . . Brown, G. (2018). Agreement between histopathologic regression and MRI Tumour Regression (mrTRG) scales used to assess response for rectal cancers. International Journal of Surgery. doi:10.1016/j.ijsu.2018.05.190

2017

Battersby, N. J., Moran, B., Stelzner, S., West, N. P., Branagan, G., Strassburg, J., . . . Brown, G. (2017). Reply to: Does MRI Restaging of Rectal Cancer After Chemoradiotherapy Actually Permit a Change in Surgical Management?. ANNALS OF SURGERY, 266(6), E116-E118. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000419022400092&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Sclafani, F., Brown, G., Cunningham, D., Wotherspoon, A., Mendes, L. S. T., Balyasnikova, S., . . . Chau, I. (2017). Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. BRITISH JOURNAL OF CANCER, 117(10), 1478-1485. doi:10.1038/bjc.2017.320

Bhoday, J., Balyasnikova, S., Wale, A., & Brown, G. (2017). How Should Imaging Direct/Orient Management of Rectal Cancer?. CLINICS IN COLON AND RECTAL SURGERY, 30(5), 297-312. doi:10.1055/s-0037-1606107

Siddiqui, M. R. S., Shanmuganandan, A. P., Rasheed, S., Tekkis, P., Brown, G., & Abulafi, A. M. (2017). An audit comparing the reporting of staging MRI scans for rectal cancer with the London Cancer Alliance (LCA) guidelines. EJSO, 43(11), 2093-2104. doi:10.1016/j.ejso.2017.09.003

Lord, A. C., D’Souza, N., Pucher, P. H., Moran, B. J., Abulafi, A. M., Wotherspoon, A., . . . Brown, G. (2017). Significance of extranodal tumour deposits in colorectal cancer: A systematic review and meta-analysis. EUROPEAN JOURNAL OF CANCER, 82, 92-102. doi:10.1016/j.ejca.2017.05.027

Sclafani, F., Brown, G., Cunningham, D., Wotherspoon, A., Mendes, L. S. T., Evans, J., . . . Chau, I. (2017). Comparison between magnetic resonance imaging (MRI) and pathology in the assessment of tumour regression grade (TRG) in rectal cancer (RC). In ANNALS OF ONCOLOGY Vol. 28 (pp. 2 pages). Madrid, SPAIN: OXFORD UNIV PRESS. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324004275&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Battersby, N. J., Dattani, M., Rao, S., Cunningham, D., Tait, D., Adams, R., . . . Brown, G. (2017). A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. TRIALS, 18, 14 pages. doi:10.1186/s13063-017-2085-2

Balyasnikova, S., Read, J., Wotherspoon, A., Rasheed, S., Tekkis, P., Tait, D., . . . Brown, G. (2017). Diagnostic accuracy of high-resolution MRI as a method to predict potentially safe endoscopic and surgical planes in patients with early rectal cancer. BMJ OPEN GASTROENTEROLOGY, 4(1), 9 pages. doi:10.1136/bmjgast-2017-000151

Sclafani, F., Brown, G., Cunningham, D., Rao, S., Tekkis, P., Tait, D., . . . Chau, I. (2017). Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. ONCOLOGIST, 22(6), 728-736. doi:10.1634/theoncologist.2016-0396

Siddiqui, M. R. S., Simillis, C., Hunter, C., Chand, M., Bhoday, J., Garant, A., . . . Brown, G. (2017). A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases. BRITISH JOURNAL OF CANCER, 116(12), 1513-1519. doi:10.1038/bjc.2017.99

Sugarbaker, P. H., Sardi, A., Brown, G., Dromain, C., Rousset, P., & Jelinek, J. S. (2017). Concerning CT features used to select patients for treatment of peritoneal metastases, a pictoral essay. INTERNATIONAL JOURNAL OF HYPERTHERMIA, 33(5), 497-504. doi:10.1080/02656736.2017.1317368

Patel, U. B., Brown, G., Machado, I., Santos-Cores, J., Pericay, C., Ballesteros, E., . . . Fernandez-Martos, C. (2017). MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial. ANNALS OF ONCOLOGY, 28(2), 344-353. doi:10.1093/annonc/mdw616

Sclafani, F., Brown, G., Cunningham, D., Rao, S., Tekkis, P. P., & Tait, D. M. (2017). Systemic chemotherapy (CT) as salvage treatment for locally advanced rectal cancer (LARC) patients (pts) who fail to respond to neoadjuvant chemoradiotherapy (CRT).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000443281700690&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Hunter, C., Siddiqui, M., Delisle, T. G., Blake, H., Jeyadevan, N., Abulafi, M., . . . Brown, G. (2017). CT and 3-T MRI accurately identify T3c disease in colon cancer, which strongly predicts disease-free survival. CLINICAL RADIOLOGY, 72(4), 307-315. doi:10.1016/j.crad.2016.11.014

Georgiou, P. A., Ali, S. M., Brown, G., Rasheed, S., & Tekkis, P. P. (2017). Extended lymphadenectomy for locally advanced and recurrent rectal cancer. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 32(3), 333-340. doi:10.1007/s00384-016-2711-6

Ciombor, K. K., Ernst, R. D., & Brown, G. (2017). Diagnosis and Diagnostic Imaging of Anal Canal Cancer. SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 26(1), 45-+. doi:10.1016/j.soc.2016.07.002

Balyasnikova, S., Haboubi, N., Moran, B., & Brown, G. (2017). Histopathological and radiological reporting in rectal cancer: concepts and controversies, facts and fantasies. TECHNIQUES IN COLOPROCTOLOGY, 21(1), 15-23. doi:10.1007/s10151-016-1555-y

Simillis, C., Baird, D. L. H., Kontovounisios, C., Pawa, N., Brown, G., Rasheed, S., & Tekkis, P. P. (2017). A Systematic Review to Assess Resection Margin Status After Abdominoperineal Excision and Pelvic Exenteration for Rectal Cancer. ANNALS OF SURGERY, 265(2), 291-299. doi:10.1097/SLA.0000000000001963

Balyasnikova, S., Read, J., Tait, D., Wotherspoon, A., Swift, I., Cunningham, D., . . . Brown, G. (2017). The results of local excision with or without postoperative adjuvant chemoradiotherapy for early rectal cancer among patients choosing to avoid radical surgery. COLORECTAL DISEASE, 19(2), 139-147. doi:10.1111/codi.13477

2016

Harris, D. A., Thorne, K., Hutchings, H., Islam, S., Holland, G., Hatcher, O., . . . Beynon, J. (2016). Protocol for a multicentre randomised feasibility trial evaluating early Surgery Alone In LOw Rectal cancer (SAILOR). BMJ OPEN, 6(11), 8 pages. doi:10.1136/bmjopen-2016-012496

Frentzas, S., Simoneau, E., Bridgeman, V. L., Vermeulen, P. B., Foo, S., Kostaras, E., . . . Reynolds, A. R. (2016). Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. NATURE MEDICINE, 22(11), 1294-1302. doi:10.1038/nm.4197

Evans, J., Bhoday, J., Sizer, B., Tekkis, P., Swift, R., Perez, R., . . . Brown, G. (2016). Results of a prospective randomised control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy?. ANNALS OF ONCOLOGY, 27, 1 page. doi:10.1093/annonc/mdw370.1

Sclafani, F., Chau, I., Cunningham, D., Vlachogiannis, G., Eltahir, Z., Lampis, A., . . . Valeri, N. (2016). KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial. ANNALS OF ONCOLOGY, 27, 1 page. doi:10.1093/annonc/mdw370.73

O’Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., . . . Waterton, J. C. (2017). Imaging biomarker roadmap for cancer studies. NATURE REVIEWS CLINICAL ONCOLOGY, 14(3), 169-186. doi:10.1038/nrclinonc.2016.162

Siddiqui, M. R. S., Bhoday, J., Battersby, N. J., Chand, M., West, N. P., Abulafi, A. -M., . . . Brown, G. (2016). Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales. WORLD JOURNAL OF GASTROENTEROLOGY, 22(37), 8414-8434. doi:10.3748/wjg.v22.i37.8414

Lutz, M. P., Zalcberg, J. R., Glynne-Jones, R., Ruers, T., Ducreux, M., Arnold, D., . . . Otto, F. (2016). Corrigendum to “2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer” [Eur J Cancer 63 (August 2016) 11-24].. Eur J Cancer, 68, 208-209. doi:10.1016/j.ejca.2016.08.017

Battersby, N. J., How, P., Moran, B. J., Stelzner, S., West, N. P., Branagan, G., . . . Pedersen, B. G. (2016). The MERCURY II Study: Prospective Validation of a Low Rectal Cancer Assessment System Using Magnetic Resonance Imaging, and Development of a Local Recurrence Risk Stratification Model. In JOURNAL OF PATHOLOGY Vol. 240 (pp. 18). Univ Nottingham, Sch Med, Acad Univ Mol Pathol Div Canc & Stem Cells, Nottingham, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000386691900075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Bhoday, J., Smith, F., Siddiqui, M. R., Balyasnikova, S., Swift, R. I., Perez, R., . . . Brown, G. (2016). Magnetic Resonance Tumor Regression Grade and Residual Mucosal Abnormality as Predictors for Pathological Complete Response in Rectal Cancer Postneoadjuvant Chemoradiotherapy. DISEASES OF THE COLON & RECTUM, 59(10), 925-933. doi:10.1097/DCR.0000000000000667

Chand, M., Rasheed, S., Heald, R., Swift, I., West, N., Rao, S., . . . Brown, G. (2017). Adjuvant chemotherapy may improve disease-free survival in patients with rectal cancer positive for MRI-detected extramural venous invasion following chemoradiation. COLORECTAL DISEASE, 19(6), 537-543. doi:10.1111/codi.13535

Kontovounisios, C., Tan, E., Pawa, N., Brown, G., Tait, D., Cunningham, D., . . . Tekkis, P. (2017). The selection process can improve the outcome in locally advanced and recurrent colorectal cancer: activity and results of a dedicated multidisciplinary colorectal cancer centre. COLORECTAL DISEASE, 19(4), 331-338. doi:10.1111/codi.13517

Siddiqui, M. R. S., Gormly, K. L., Bhoday, J., Balyansikova, S., Battersby, N. J., Chand, M., . . . Brown, G. (2016). Interobserver agreement of radiologists assessing the response of rectal cancers to preoperative chemoradiation using the MRI tumour regression grading (mrTRG). CLINICAL RADIOLOGY, 71(9), 854-862. doi:10.1016/j.crad.2016.05.005

Pearson, A., Smyth, E., Babina, I. S., Herrera-Abreu, M. T., Tarazona, N., Peckitt, C., . . . Turner, N. C. (2016). High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. CANCER DISCOVERY, 6(8), 838-851. doi:10.1158/2159-8290.CD-15-1246

Sclafani, F., Chau, I., Cunningham, D., Lampis, A., Hahne, J. C., Ghidini, M., . . . Valeri, N. (2016). Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. CARCINOGENESIS, 37(9), 852-857. doi:10.1093/carcin/bgw073

Hunter, C., Blake, H., Jeyadevan, N., Abulafi, M., Swift, I., Toomey, P., & Brown, G. (2016). Local staging and assessment of colon cancer with 1.5-T magnetic resonance imaging. BRITISH JOURNAL OF RADIOLOGY, 89(1064), 9 pages. doi:10.1259/bjr.20160257

Balyasnikova, S., & Brown, G. (2016). Optimal Imaging Strategies for Rectal Cancer Staging and Ongoing Management. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 17(6), 11 pages. doi:10.1007/s11864-016-0403-7

Lutz, M. P., Zalcberg, J. R., Glynne-Jones, R., Ruers, T., Ducreux, M., Arnold, D., . . . Otto, F. (2016). Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. EUROPEAN JOURNAL OF CANCER, 63, 11-24. doi:10.1016/j.ejca.2016.04.010

Sclafani, F., Brown, G., Cunningham, D., Wotherspoon, A., Tait, D., Peckitt, C., . . . Chau, I. (2016). PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. ANNALS OF ONCOLOGY, 27(8), 1557-1565. doi:10.1093/annonc/mdw215

Hunter, C., & Brown, G. (2016). Pre-operative staging of rectal cancer: a review of imaging techniques. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 10(9), 1011-1025. doi:10.1080/17474124.2016.1179577

Battersby, N. J., How, P., Moran, B., Stelzner, S., West, N. P., Branagan, G., . . . Brown, G. (2016). Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study. ANNALS OF SURGERY, 263(4), 751-760. doi:10.1097/SLA.0000000000001193

Balyasnikova, S., & Brown, G. (2016). Imaging Advances in Colorectal Cancer. CURRENT COLORECTAL CANCER REPORTS, 12(3), 162-169. doi:10.1007/s11888-016-0321-x

West, M. A., Dimitrov, B. D., Moyses, H. E., Kemp, G. J., Loughney, L., White, D., . . . Brown, G. (2016). Timing of surgery following neoadjuvant chemoradiotherapy in locally advanced rectal cancer – A comparison of magnetic resonance imaging at two time points and histopathological responses. EJSO, 42(9), 1350-1358. doi:10.1016/j.ejso.2016.04.003

Sclafani, F., & Brown, G. (2016). Extramural Venous Invasion (EMVI) and Tumour Regression Grading (TRG) as Potential Prognostic Factors for Risk Stratification and Treatment Decision in Rectal Cancer. CURRENT COLORECTAL CANCER REPORTS, 12(3), 130-140. doi:10.1007/s11888-016-0319-4

Siddiqui, M. R. S., Balyansikova, S., Bhoday, J., Chand, M., Rao, S., Tekkis, P., . . . Brown, G. (2016). MRI assessment of intraluminal and extramural regression after chemoradiation therapy. In BRITISH JOURNAL OF SURGERY Vol. 103 (pp. 18). Royal Coll Surg England, London, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000374301300046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Siddiqui, M. R. S., Bhoday, J., Balyansikova, S., Battersby, N. J., Gormly, K. L., Rao, S., . . . Brown, G. (2016). Inter-observer agreement of radiologists assessing the response of rectal cancers after chemoradiation therapy according to MRI tumour regression grading (mrTRG). In BRITISH JOURNAL OF SURGERY Vol. 103 (pp. 17). Royal Coll Surg England, London, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000374301300043&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Siddiqui, M. R. S., Chand, M., Bhoday, J., Tekkis, P., Abulafi, A. M., & Brown, G. (2016). Correlation between MRI detected extra-mural vascular invasion (mrEMVI) in rectal cancer and metastatic disease: a meta-analysis. In BRITISH JOURNAL OF SURGERY Vol. 103 (pp. 19). Royal Coll Surg England, London, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000374301300049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Hill, E. J., Roberts, C., Franklin, J. M., Enescu, M., West, N., MacGregor, T. P., . . . Sharma, R. A. (2016). Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer. CLINICAL CANCER RESEARCH, 22(8), 1922-1931. doi:10.1158/1078-0432.CCR-15-1489

Smyth, E. C., Turner, N. C., Pearson, A., Peckitt, C., Chau, I., Watkins, D. J., . . . Cunningham, D. (2016). Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. doi:10.1200/jco.2016.34.4_suppl.154

Chand, M., Siddiqui, M. R. S., Swift, I., & Brown, G. (2016). Systematic review of prognostic importance of extramural venous invasion in rectal cancer. WORLD JOURNAL OF GASTROENTEROLOGY, 22(4), 1721-1726. doi:10.3748/wjg.v22.i4.1721

2015

Smyth, E. C., Turner, N., Pearson, A., Peckitt, C., Chau, I., Watkins, D., . . . Cunningham, D. (2015). Phase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort clinical and translational results. In ANNALS OF ONCOLOGY Vol. 26 (pp. 44). Singapore, SINGAPORE: OXFORD UNIV PRESS. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000367158700145&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Tekkis, P., Tan, E., Kontovounisios, C., Kinross, J., Georgiou, C., Nicholls, R. J., . . . Brown, G. (2015). Hand-sewn coloanal anastomosis for low rectal cancer: technique and long-term outcome. COLORECTAL DISEASE, 17(12), 1062-1070. doi:10.1111/codi.13028

Machado, I., Patel, U., Brown, G., Salud, A., Gil, M., Montagut, C., . . . Fernandez-Martos, C. (2015). The prognostic significance of radiologic and pathologic factors after neoadyuvant chemotherapy for T3 rectal cancer (RC): 3-years update GEMCAD 0801 trial. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S387). Vienna, AUSTRIA: ELSEVIER SCI LTD. doi:10.1016/S0959-8049(16)31082-6

Sclafani, F., Chau, I., Cunningham, D., Peckitt, C., Lampis, A., Hahne, J. C., . . . Valeri, N. (2015). Prognostic role of the LCS-6 KRAS variant in locally advanced rectal cancer: Results of the EXPERT-C trial. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S396). Vienna, AUSTRIA: ELSEVIER SCI LTD. doi:10.1016/S0959-8049(16)31107-8

West, M. A., Grocott, M. P. W., Jack, S., Kemp, G. J., & Brown, G. (2015). Exercise training response is associated with greater tumour regression in rectal cancer following neoadjuvant chemoradiotherapy. In BRITISH JOURNAL OF SURGERY Vol. 102 (pp. 55). Manchester, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368130400175&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Hugen, N., Brown, G., Glynne-Jones, R., de Wilt, J. H. W., & Nagtegaal, I. D. (2016). Advances in the care of patients with mucinous colorectal cancer. NATURE REVIEWS CLINICAL ONCOLOGY, 13(6), 361-369. doi:10.1038/nrclinonc.2015.140

Sclafani, F., Chau, I., Cunningham, D., Peckitt, C., Lampis, A., Hahne, J. C., . . . Valeri, N. (2015). Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. ANNALS OF ONCOLOGY, 26(9), 1936-1941. doi:10.1093/annonc/mdv285

Gollins, S., Sebag-Montefiore, D., Adams, R., Saunders, M. P., Grieve, R., Scott, N., . . . Hurt, C. (2015). A phase II single arm feasibility trial of neoadjuvant chemotherapy (NAC) with oxaliplatin/fluorouracil (OxMdG) then short-course preoperative radiotherapy (SCPRT) then immediate surgery in operable rectal cancer (ORC): COPERNICUS (NCT01263171). In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036900828&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Sclafani, F., Peckitt, C., Cunningham, D., Tait, D., Giralt, J., Glimelius, B., . . . Chau, I. (2015). Short-and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93(2), 303-312. doi:10.1016/j.ijrobp.2015.03.038

Chand, M., Palmer, T., Blomqvist, L., Nagtegaal, I., West, N., & Brown, G. (2015). Evidence for radiological and histopathological prognostic importance of detecting extramural venous invasion in rectal cancer: recommendations for radiology and histopathology reporting. COLORECTAL DISEASE, 17(6), 468-473. doi:10.1111/codi.12920

Machado, I., Brown, G., Estevan, R., Salud, A., Gil, M., Montagut, C., . . . Fernandez-Martos, C. (2015). Radiologic and pathologic prognostic factors after neoadyuvant chemotherapy for T3 rectal cancer (RC): 3-year update GEMCAD 0801-trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. doi:10.1200/jco.2015.33.3_suppl.643

Sclafani, F., Chau, I., Cunningham, D., Lampis, A., Hahne, J., Braconi, C., . . . Valeri, N. (2015). Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. doi:10.1200/jco.2015.33.3_suppl.581

2014

Slesser, A. A. P., Khan, F., Chau, I., Khan, A. Z., Mudan, S., Tekkis, P. P., . . . Rao, S. (2015). The effect of a primary tumour resection on the progression of synchronous colorectal liver metastases: An exploratory study. EJSO, 41(4), 484-492. doi:10.1016/j.ejso.2014.12.009

Chand, M., Balyasnikova, S., & Brown, G. (2015). The role of imaging in the diagnosis and staging of primary and recurrent rectal cancer. In Modern Management of Cancer of the Rectum (pp. 81-96). doi:10.1007/978-1-4471-6609-2_6

Rymer, B., Chand, M., Bhangu, A., Swift, I., & Brown, G. (2015). FDG-PET-CT can be used to Assess the Response of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiotherapy: Evidence from Meta-Analysis. In BRITISH JOURNAL OF SURGERY Vol. 102 (pp. 184-185). Harrogate, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000346489701210&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Siddiqui, M., Bhoday, J., Abulafi, M. A., Tekkis, P., & Brown, G. (2015). Defining Poor Response after Neoadjuvant Therapy in Patients with Rectal Cancer. In BRITISH JOURNAL OF SURGERY Vol. 102 (pp. 28). Harrogate, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000346489700075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Messager, M., Brown, G., & Allum, W. H. (2014). MDCT for Staging of Oesophageal and Junctional Cancer: Do we need a Dedicated Reporting Template?. In BRITISH JOURNAL OF SURGERY Vol. 101 (pp. 38). Brighton, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345329400126&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Brown, G., & Evans, J. (2014). Timing of surgery following chemoradiotherapy in rectal Cancer.. Indian J Med Paediatr Oncol, 35(4), 235-236. doi:10.4103/0971-5851.144959

Kontovounisios, C., Kinross, J., Tan, E., Brown, G., Rasheed, S., & Tekkis, P. (2015). Complete mesocolic excision in colorectal cancer: a systematic review. COLORECTAL DISEASE, 17(1), 7-16. doi:10.1111/codi.12793

Frentzas, S., Thompson, V. L., Vermeulen, P. B., Foo, S., Brown, G., Cunningham, D., & Reynolds, A. R. (2014). Vessel co-option in colorectal cancer liver metastases mediates resistance to VEGF-targeted therapy. In CANCER RESEARCH Vol. 74 (pp. 1 page). San Diego, CA: AMER ASSOC CANCER RESEARCH. doi:10.1158/1538-7445.AM2014-2997

2014

Khan, K., Wale, A., Brown, G., & Chau, I. (2014). Colorectal cancer with liver metastases: Neoadjuvant chemotherapy, surgical resection first or palliation alone?. WORLD JOURNAL OF GASTROENTEROLOGY, 20(35), 12391-12406. doi:10.3748/wjg.v20.i35.12391

Chand, M., Evans, J., Swift, R. I., Tekkis, P. P., West, N. P., Stamp, G., . . . Brown, G. (2015). The Prognostic Significance of Postchemoradiotherapy High-resolution MRI and Histopathology Detected Extramural Venous Invasion in Rectal Cancer. ANNALS OF SURGERY, 261(3), 473-479. doi:10.1097/SLA.0000000000000848

Chand, M., Brown, G., Tekkis, P., & Heald, R. J. (2014). Total mesorectal excision optimized by pelvic MRI. COLORECTAL DISEASE, 16(11), 847-853. doi:10.1111/codi.12773

Fernandez-Martos, C., Brown, G., Estevan, R., Salud, A., Montagut, C., Maurel, J., . . . Pericay, C. (2014). Preoperative Chemotherapy in Patients With Intermediate-Risk Rectal Adenocarcinoma Selected by High-Resolution Magnetic Resonance Imaging: The GEMCAD 0801 Phase II Multicenter Trial. ONCOLOGIST, 19(10), 1042-1043. doi:10.1634/theoncologist.2014-0233

Georgiou, P. A., Bhangu, A., Brown, G., Rasheed, S., Nicholls, R. J., & Tekkis, P. P. (2015). Learning curve for the management of recurrent and locally advanced primary rectal cancer: a single team’s experience. COLORECTAL DISEASE, 17(1), 57-65. doi:10.1111/codi.12772

Battersby, N. J., Balyasnikova, S., & Brown, G. (2014). Guiding Post-Treatment Decisions in Rectal Cancer: mrTRG Is a Practical Place to Start. ONCOLOGY-NEW YORK, 28(8), 677-680. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000340866000003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Wale, A., & Brown, G. (2014). A practical review of the performance and interpretation of staging magnetic resonance imaging for rectal cancer.. Top Magn Reson Imaging, 23(4), 213-223. doi:10.1097/RMR.0000000000000028

Sclafani, F., Gonzalez, D., Cunningham, D., Wilson, S. H., Peckitt, C., Tabernero, J., . . . Chau, I. (2014). TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 106(7), 4 pages. doi:10.1093/jnci/dju121

Thompson, V., Frentzas, S., Vermeulen, P., Foo, S., Eltahir, Z., Brown, G., . . . Reynolds, A. R. (2014). Proffered Paper: Vessel co-option in colorectal cancer liver metastases mediates resistance to conventional anti-angiogenic therapy. EUROPEAN JOURNAL OF CANCER, 50, S9. doi:10.1016/S0959-8049(14)50032-9

Sclafani, F., de Castro, D. G., Cunningham, D., Wilson, S. H., Peckitt, C., Capdevila, J., . . . Chau, I. (2014). Fc gamma RIIa and Fc gamma RIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease. CLINICAL CANCER RESEARCH, 20(17), 4511-4519. doi:10.1158/1078-0432.CCR-14-0674

Bhangu, A., Rasheed, S., Brown, G., Tait, D., Cunningham, D., & Tekkis, P. (2014). Does rectal cancer height influence the oncological outcome?. COLORECTAL DISEASE, 16(10), 801-808. doi:10.1111/codi.12703

Chand, M., Siddiqui, M. R. S., Rasheed, S., Brown, G., Tekkis, P., Parvaiz, A., & Qureshi, T. (2014). A systematic review and meta-analysis evaluating the role of laparoscopic surgical resection of transverse colon tumours. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 28(12), 3263-3272. doi:10.1007/s00464-014-3634-3

Battersby, N. J., Moran, B., Yu, S., Tekkis, P., & Brown, G. (2014). MR imaging for rectal cancer: the role in staging the primary and response to neoadjuvant therapy. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 8(6), 703-719. doi:10.1586/17474124.2014.906898

Kennedy, E. D., Milot, L., Fruitman, M., Al-Sukhni, E., Heine, G., Schmocker, S., . . . McLeod, R. S. (2014). Development and Implementation of a Synoptic MRI Report for Preoperative Staging of Rectal Cancer on a Population-Based Level. DISEASES OF THE COLON & RECTUM, 57(6), 700-708. doi:10.1097/DCR.0000000000000123

Sclafani, F., Peckitt, C., Cunningham, D., Evans, J., Brown, G., Tabernero, J., . . . Chau, I. (2014). Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. doi:10.1200/jco.2014.32.15_suppl.3575

Watkins, D. J., Starling, N., Cunningham, D., Thomas, J., Webb, J., Brown, G., . . . Chau, I. (2014). The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. EUROPEAN JOURNAL OF CANCER, 50(8), 1422-1429. doi:10.1016/j.ejca.2014.02.003

Chand, M., Bhangu, A., Wotherspoon, A., Stamp, G. W. H., Swift, R. I., Chau, I., . . . Brown, G. (2014). EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. ANNALS OF ONCOLOGY, 25(4), 858-863. doi:10.1093/annonc/mdu029

Chand, M., & Brown, G. (2014). Important imaging considerations in the pre-operative assessment of rectal cancer. Seminars in Colon and Rectal Surgery, 25(1), 6-12. doi:10.1053/j.scrs.2013.11.001

Bhangu, A., Kiran, R. P., Brown, G., Goldin, R., & Tekkis, P. (2014). Establishing the optimum lymph node yield for diagnosis of stage III rectal cancer. TECHNIQUES IN COLOPROCTOLOGY, 18(8), 709-717. doi:10.1007/s10151-013-1114-8

Bhangu, A., Ali, S. M., Brown, G., Nicholls, R. J., & Tekkis, P. (2014). Indications and Outcome of Pelvic Exenteration for Locally Advanced Primary and Recurrent Rectal Cancer. ANNALS OF SURGERY, 259(2), 315-322. doi:10.1097/SLA.0b013e31828a0d22

Khan, K. H., Wale, A., McCall, J., Wijesekera, N., Khan, N., Chau, I., & Brown, G. (2014). The impact of treatment intent on overall survival after radiofrequency ablation of colorectal cancer liver metastases: The Royal Marsden Hospital experience.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. doi:10.1200/jco.2014.32.3_suppl.622

Sclafani, F., Gonzalez, D., Cunningham, D., Wilson, S. H., Peckitt, C., Tabernero, J., . . . Chau, I. (2014). RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. doi:10.1200/jco.2014.32.3_suppl.489

Hill, E. J., Enescu, M., West, N., Franklin, J. M., Chu, K. -Y., Li, J., . . . Sharma, R. A. (2014). Oral nelfinavir before and during radiation therapy for rectal cancer: Changes in tumor perfusion and correlation between tissue and radiological markers of response.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. doi:10.1200/jco.2014.32.3_suppl.491

Astin, R., Jack, S., Loughney, L., Barben, C., Grocott, M., Brown, G., & West, M. A. (2014). Training Response To A Structured Exercise Program Is Associated With Greater Tumour Regression In Rectal Cancer Following Neoadjuvant Chemoradiotherapy. In AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Vol. 189 (pp. 2 pages). AMER THORACIC SOC. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209838206461&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Sondenaa, K., Quirke, P., Hohenberger, W., Sugihara, K., Kobayashi, H., Kessler, H., . . . Moran, B. (2014). The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 29(4), 419-428. doi:10.1007/s00384-013-1818-2

Watkins, D. J., Starling, N., Chau, I., Thomas, J., Webb, J., Oates, J. R., . . . Cunningham, D. (2010). The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma : The TARGET study.. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. doi:10.1200/jco.2010.28.15_suppl.4036

Sclafani, F., Gonzalez, D., Cunningham, D., Wilson, S. H., Peckitt, C., Giralt, J., . . . Chau, I. (2014). RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial. EUROPEAN JOURNAL OF CANCER, 50(8), 1430-1436. doi:10.1016/j.ejca.2014.02.002

Yu, S. K. T., Chand, M., Tait, D. M., & Brown, G. (2014). Magnetic resonance imaging defined mucinous rectal carcinoma is an independent imaging biomarker for poor prognosis and poor response to preoperative chemoradiotherapy. EUROPEAN JOURNAL OF CANCER, 50(5), 920-927. doi:10.1016/j.ejca.2013.12.007

Chand, M., Moran, B. J., Jones, R. G., Heald, R. J., & Brown, G. (2014). Lymph Node Status Does Not Predict Local Recurrence in the Total Mesorectal Excision Era. DISEASES OF THE COLON & RECTUM, 57(1), 127-129. doi:10.1097/DCR.0000000000000001

Waage, J., Taylor, F., Read, J., & Brown, G. (2014). Imaging assessment of early rectal cancer.. Recent Results Cancer Res, 203, 3-14. doi:10.1007/978-3-319-08060-4_1

Battersby, N. J., Balyasnikova, S., & Brown, G. (2014). Guiding post-treatment decisions in rectal cancer: mrTRG is a practical place to start.. Oncology (Williston Park, N.Y.), 28(8), 677-680.

Tudyka, V., Blomqvist, L., Beets-Tan, R. G. H., Boelens, P. G., Valentini, V., van de Velde, C. J., . . . Brown, G. (2014). EURECCA consensus conference highlights about colon & rectal cancer multidisciplinary management: The radiology experts review. EJSO, 40(4), 469-475. doi:10.1016/j.ejso.2013.10.029

Chand, M., Swift, R. I., Chau, I., Heald, R. J., Tekkis, P. P., & Brown, G. (2014). Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancer. ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 96(7), 543-546. doi:10.1308/003588414X13814021678835

Yu, S. K. T., Bhangu, A., Tait, D. M., Tekkis, P., Wotherspoon, A., & Brown, G. (2014). Chemoradiotherapy response in recurrent rectal cancer. CANCER MEDICINE, 3(1), 111-117. doi:10.1002/cam4.169

Chand, M., Yu, S., Swift, R. I., & Brown, G. (2014). Mucinous carcinoma of the rectum: a distinct clinicopathological entity. TECHNIQUES IN COLOPROCTOLOGY, 18(4), 335-344. doi:10.1007/s10151-013-1099-3

Chand, M., Swift, R. I., Tekkis, P. P., Chau, I., & Brown, G. (2014). Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. BRITISH JOURNAL OF CANCER, 110(1), 19-25. doi:10.1038/bjc.2013.603

Bhangu, A., Kiran, R. P., Slesser, A., Fitzgerald, J. E., Brown, G., & Tekkis, P. (2013). Survival After Resection of Colorectal Cancer Based on Anatomical Segment of Involvement. ANNALS OF SURGICAL ONCOLOGY, 20(13), 4161-4168. doi:10.1245/s10434-013-3104-5

Taylor, F. G. M., Quirke, P., Heald, R. J., Moran, B. J., Blomqvist, L., Swift, I. R., . . . Brown, G. (2014). Preoperative Magnetic Resonance Imaging Assessment of Circumferential Resection Margin Predicts Disease-Free Survival and Local Recurrence: 5-Year Follow-Up Results of the MERCURY Study. JOURNAL OF CLINICAL ONCOLOGY, 32(1), 34-U114. doi:10.1200/JCO.2012.45.3258

How, P., West, N. P., & Brown, G. (2014). An MRI-based Assessment of Standard and Extralevator Abdominoperineal Excision Specimens: Time for a Patient Tailored Approach?. ANNALS OF SURGICAL ONCOLOGY, 21(3), 822-828. doi:10.1245/s10434-013-3378-7

Moran, B. J., Holm, T., Brannagan, G., Chave, H., Quirke, P., West, N., . . . McMeeking, A. (2014). The English National Low Rectal Cancer Development Programme: key messages and future perspectives. COLORECTAL DISEASE, 16(3), 173-178. doi:10.1111/codi.12501

Chand, M., Rasheed, S., Bhangu, A., Stamp, G. W. H., Swift, R. I., Tekkis, P. P., & Brown, G. (2014). Adjuvant chemotherapy improves overall survival after TME surgery in mucinous carcinoma of the rectum. EJSO, 40(2), 240-245. doi:10.1016/j.ejso.2013.11.005

Bhangu, A., Wood, G., Brown, G., Darzi, A., Tekkis, P., & Goldin, R. (2014). The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer. COLORECTAL DISEASE, 16(4), O133-O143. doi:10.1111/codi.12482

2013

Yu, S. K. T., Tait, D., Chau, I., & Brown, G. (2013). MRI Predictive Factors for Tumor Response in Rectal Cancer Following Neoadjuvant Chemoradiation Therapy – Implications for Induction Chemotherapy?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(3), 505-511. doi:10.1016/j.ijrobp.2013.06.2052

van de Velde, C. J. H., Boelens, P. G., Borras, J. M., Coebergh, J. -W., Cervantes, A., Blomqvist, L., . . . Valentini, V. (2014). EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. EUROPEAN JOURNAL OF CANCER, 50(1), 34 pages. doi:10.1016/j.ejca.2013.06.048

Tam, H. H., Collins, D. J., Brown, G., Chau, I., Cunningham, D., Leach, M. O., & Koh, D. -M. (2013). The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis. BRITISH JOURNAL OF RADIOLOGY, 86(1030), 8 pages. doi:10.1259/bjr.20130281

Chand, M., Heald, R. J., & Brown, G. (2013). The importance of not overstaging mesorectal lymph nodes seen on MRI. COLORECTAL DISEASE, 15(10), 1201-1204. doi:10.1111/codi.12435

Bhangu, A., Kiran, R., Patel, P., Brown, G., & Tekkis, P. (2013). Survival after resection of colorectal cancer based on anatomical segment of involvement. BRITISH JOURNAL OF SURGERY, 100, 62. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326083400186&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Slesser, A. A. P., Chand, M., Goldin, R., Brown, G., Tekkis, P. P., & Mudan, S. (2013). Outcomes of simultaneous resections for patients with synchronous colorectal liver metastases. EJSO, 39(12), 1384-1393. doi:10.1016/j.ejso.2013.09.012

Sclafani, F., Cunningham, D., Tabernero, J., Glimelius, B., Cervantes, A., Peckitt, C., . . . Chau, I. (2013). Updated survival analysis of EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab in MRI-defined high risk rectal cancer patients. In EUROPEAN JOURNAL OF CANCER Vol. 49 (pp. S487). Amsterdam, NETHERLANDS: ELSEVIER SCI LTD. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843603224&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Sclafani, F., Gonzalez, D., Cunningham, D., Wilson, S. H., Peckitt, C., Tabernero, J., . . . Chau, I. (2013). TP53 status may predict benefit from cetuximab in high-risk, locally advanced rectal cancer: Results of the EXPERT-C trial. EUROPEAN JOURNAL OF CANCER, 49, S4. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209470600012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Chand, M., & Brown, G. (2013). Pre-operative staging of rectal cancer: MRI or ultrasound?. Seminars in Colon and Rectal Surgery, 24(3), 114-118. doi:10.1053/j.scrs.2013.03.002

van de Velde, C. J. H., Aristei, C., Boelens, P. G., Beets-Tan, R. G. H., Blomqvist, L., Borras, J. M., . . . Valentini, V. (2013). EURECCA colorectal: Multidisciplinary Mission statement on better care for patients with colon and rectal cancer in Europe. EUROPEAN JOURNAL OF CANCER, 49(13), 2784-2790. doi:10.1016/j.ejca.2013.04.032

Bhangu, A., Brown, G., Nicholls, R. J., Wong, J., Darzi, A., & Tekkis, P. (2013). Survival Outcome of Local Excision versus Radical Resection of Colon or Rectal Carcinoma A Surveillance, Epidemiology, and End Results (SEER) Population-Based Study. ANNALS OF SURGERY, 258(4), 563-571. doi:10.1097/SLA.0b013e3182a4e85a

Nougaret, S., Reinhold, C., Mikhael, H. W., Rouanet, P., Bibeau, F., & Brown, G. (2013). The Use of MR Imaging in Treatment Planning for Patients with Rectal Carcinoma: Have You Checked the “DISTANCE”?. RADIOLOGY, 268(2), 329-343. doi:10.1148/radiol.13121361

Dighe, S., Blake, H., Jeyadevan, N., Castellano, I., Koh, D. -M., Orton, M., . . . Brown, G. (2013). Perfusion CT Vascular Parameters Do Not Correlate with Immunohistochemically Derived Microvessel Density Count in Colorectal Tumors. RADIOLOGY, 268(2), 400-410. doi:10.1148/radiol.13112460

Bott, R., Chand, M., Bhoday, J., Swift, R. I., & Brown, G. (2013). MRI-detected EMVI (Mremvi) should be considered in addition to histopathological EMVI status with regards to treatment decisions in rectal cancer. In BRITISH JOURNAL OF SURGERY Vol. 100 (pp. 130-131). Glasgow, SCOTLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326083400392&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Bhangu, A., Beynon, J., Brown, G., Chang, G., Das, P., Desai, A., . . . Woodhouse, C. (2013). Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. BRITISH JOURNAL OF SURGERY, 100(8), E1-E33. doi:10.1002/bjs.9192

Patel, U. B., & Brown, G. (2013). MRI-based assessment of tumor regression in rectal cancer. Current Colorectal Cancer Reports, 9(2), 136-145. doi:10.1007/s11888-013-0169-2

Bott, R. K., Chand, M., Nash, G. F., Swift, R. I., & Brown, G. (2013). The role of MRI in treatment planning for rectal cancer – a review. Current Cancer Therapy Reviews, 9(2), 111-116. doi:10.2174/1573394711309020003

Costa-Silva, L., & Brown, G. (2013). Magnetic Resonance Imaging of Rectal Cancer. MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA, 21(2), 385-+. doi:10.1016/j.mric.2013.01.006

Bhangu, A., Fitzgerald, E., Brown, G., & Tekkis, P. (2012). Indications and outcomes of abdominosacral resection for locally advanced primary and recurrent rectal cancer. BRITISH JOURNAL OF SURGERY, 99, 106-107. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000306123100325&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Slesser, A. A. P., Simillis, C., Goldin, R., Brown, G., Mudan, S., & Tekkis, P. P. (2013). A meta-analysis comparing simultaneous versus delayed resections in patients with synchronous colorectal liver metastases. SURGICAL ONCOLOGY-OXFORD, 22(1), 36-47. doi:10.1016/j.suronc.2012.11.002

Bhangu, A., Ali, S. M., Cunningham, D., Brown, G., & Tekkis, P. (2013). Comparison of long-term survival outcome of operative vs nonoperative management of recurrent rectal cancer. COLORECTAL DISEASE, 15(2), 156-163. doi:10.1111/j.1463-1318.2012.03123.x

Slesser, A. A. P., Georgiou, P., Brown, G., Mudan, S., Goldin, R., & Tekkis, P. (2013). The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review. CLINICAL & EXPERIMENTAL METASTASIS, 30(4), 457-470. doi:10.1007/s10585-012-9551-8

Morton, U. K. D., Seymour, M., Magill, L., Handley, K., Brown, G., Ferry, D., . . . Gray, R. (2012). Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. LANCET ONCOLOGY, 13(11), 1152-1160. doi:10.1016/S1470-2045(12)70348-0

Dighe, S., Castellano, E., Blake, H., Jeyadevan, N., Koh, M. U., Orten, M., . . . Brown, G. (2012). Perfusion CT to assess angiogenesis in colon cancer: technical limitations and practical challenges. BRITISH JOURNAL OF RADIOLOGY, 85(1018), E814-E825. doi:10.1259/bjr/19855447

Bhangu, A., Brown, G., Akmal, M., & Tekkis, P. (2012). Outcome of abdominosacral resection for locally advanced primary and recurrent rectal cancer. BRITISH JOURNAL OF SURGERY, 99(10), 1453-1461. doi:10.1002/bjs.8881

Patel, U. B., Blomqvist, L. K., Taylor, F., George, C., Guthrie, A., Bees, N., & Brown, G. (2012). MRI After Treatment of Locally Advanced Rectal Cancer: How to Report Tumor Response-The MERCURY Experience. AMERICAN JOURNAL OF ROENTGENOLOGY, 199(4), W486-W495. doi:10.2214/AJR.11.8210

Chand, M., Bhoday, J., Brown, G., Moran, B., & Parvaiz, A. (2012). Laparoscopic surgery for rectal cancer. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 105(10), 429-435. doi:10.1258/jrsm.2012.120070

Georgiou, P. A., Tekkis, P. P., Constantinides, V. A., Patel, U., Goldin, R. D., Darzi, A. W., . . . Brown, G. (2013). Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal cancer. EUROPEAN JOURNAL OF CANCER, 49(1), 72-81. doi:10.1016/j.ejca.2012.06.025

Slesser, A. A. P., Bhangu, A., Brown, G., Mudan, S., & Tekkis, P. P. (2013). The management of rectal cancer with synchronous liver metastases: a modern surgical dilemma. TECHNIQUES IN COLOPROCTOLOGY, 17(1), 1-12. doi:10.1007/s10151-012-0888-4

2012

Hunter, C., Brown, G., Temple, L., Abulafi, M., & Arnaout, A. (2012). Magnetic resonance imaging assisted tumour block selection in colorectal cancer. VIRCHOWS ARCHIV, 461, S179. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310364801512&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Patel, U. B., Brown, G., Rutten, H., West, N., Sebag-Montefiore, D., Glynne-Jones, R., . . . Quirke, P. (2012). Comparison of Magnetic Resonance Imaging and Histopathological Response to Chemoradiotherapy in Locally Advanced Rectal Cancer. ANNALS OF SURGICAL ONCOLOGY, 19(9), 2842-2852. doi:10.1245/s10434-012-2309-3

Shihab, O. C., Heald, R. J., Holm, T., How, P. D., Brown, G., Quirke, P., & Moran, B. J. (2012). A pictorial description of extralevator abdominoperineal excision for low rectal cancer. COLORECTAL DISEASE, 14(10), E655-E660. doi:10.1111/j.1463-1318.2012.03181.x

Al-Sukhni, E., Milot, L., Fruitman, M., Beyene, J., Victor, J. C., Schmocker, S., . . . Kennedy, E. (2012). Diagnostic Accuracy of MRI for Assessment of T Category, Lymph Node Metastases, and Circumferential Resection Margin Involvement in Patients with Rectal Cancer: A Systematic Review and Meta-analysis. ANNALS OF SURGICAL ONCOLOGY, 19(7), 2212-2223. doi:10.1245/s10434-011-2210-5

How, P., Evans, J., Moran, B., Swift, I., & Brown, G. (2012). Preoperative MRI sphincter morphology and anal manometry: can they be markers of functional outcome following anterior resection for rectal cancer?. COLORECTAL DISEASE, 14(6), E339-E345. doi:10.1111/j.1463-1318.2012.02942.x

Dewdney, A., Chau, I., Capdevila, J., Glimelius, B., Cervantes-Ruiperez, A., Tait, D. M., . . . Cunningham, D. (2012). The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009804716&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Fernandez-Martos, C., Estevan, R., Salud, A., Pericay, C., Gallen, M., Sierra, E., . . . Brown, G. (2012). Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009803825&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Brown, G., Bharat Patel, U., Santos Cores, J., Gil Garcia, M. I., Ramon Ayuso, J., Puchades Roman, I., . . . Fernandez-Martos, C. (2012). Comparison of magnetic resonance imaging and histopathological response to neoadjuvant chemotherapy in locally advanced rectal cancer: The GEMCAD 0801 trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802738&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Bhangu, A., Ali, M., Cunningham, D., Brown, G., & Tekkis, P. P. (2012). Comparison of long-term survival outcomes of operative versus nonoperative management of recurrent rectal cancer. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009800867&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Dewdney, A., Cunningham, D., Tabernero, J., Capdevila, J., Glimelius, B., Cervantes, A., . . . Chau, I. (2012). Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C). JOURNAL OF CLINICAL ONCOLOGY, 30(14), 1620-1627. doi:10.1200/JCO.2011.39.6036

Dighe, S., Swift, I., Magill, L., Handley, K., Gray, R., Quirke, P., . . . Brown, G. (2012). Accuracy of radiological staging in identifying high-risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience. COLORECTAL DISEASE, 14(4), 438-444. doi:10.1111/j.1463-1318.2011.02638.x

Starling, N., Hawkes, E. A., Chau, I., Watkins, D., Thomas, J., Webb, J., . . . Cunningham, D. (2012). A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. ANNALS OF ONCOLOGY, 23(4), 942-947. doi:10.1093/annonc/mdr317

Brown, G., Evans, J., Tait, D., Swift, I., Tekkis, P., Wotherspoon, A., & Chau, I. (2012). Timing of Surgery Following Preoperative Therapy in Rectal Cancer: There Is No Need for a Prospective Randomized Trial Reply. DISEASES OF THE COLON & RECTUM, 55(3), E31-E32. doi:10.1097/DCR.0b013e31823f86dd

West, N., Hemmings, G. J., Richman, S. D., Taylor, M., Chambers, P., Magill, L., . . . Quirke, P. (2012). KRAS and BRAF Mutational Status can be Accurately Determined on Diagnostic Tissue Biopsies: An Analysis of Matched Biopsy and Resection Material from Patients with Colon Cancer in the NCRI FOxTROT trial. In JOURNAL OF PATHOLOGY Vol. 226 (pp. S4). Dept Cellular Pathol, London, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000300669800010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

West, N., Tinkler-Hundal, E., Handley, K., Magill, L., Lancaster, D., Seymour, M., . . . Quirke, P. (2012). Histopathological Downstaging of Colon Cancer Following Six Weeks of Pre-operative Chemotherapy: Early Results of the NCRI FOxTROT Trial. In JOURNAL OF PATHOLOGY Vol. 226 (pp. S23). Dept Cellular Pathol, London, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000300669800083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Bhangu, A., Ali, S. M., Darzi, A., Brown, G., & Tekkis, P. (2012). Meta-analysis of survival based on resection margin status following surgery for recurrent rectal cancer. COLORECTAL DISEASE, 14(12), 1457-1466. doi:10.1111/j.1463-1318.2012.03005.x

Yu, S. K., Brown, G., & Tait, D. M. (2012). Use of MRI-defined tumor distance from the anal verge to predict tumor response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.. J Clin Oncol, 30(4_suppl), 573. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27983202

Currie, A. C., Evans, J., Smith, N. J., Brown, G., Abulafi, A. M., & Swift, R. I. (2012). The impact of the two-week wait referral pathway on rectal cancer survival. COLORECTAL DISEASE, 14(7), 848-853. doi:10.1111/j.1463-1318.2011.02829.x

Brown, G. (2012). Specialist multidisciplinary team working in the treatment of cancer Improves survival, possibly through enabling bolder treatment. BMJ-BRITISH MEDICAL JOURNAL, 344, 2 pages. doi:10.1136/bmj.e2780

Tam, H. H., Collins, D. J., Wallace, T., Brown, G., Riddell, A., & Koh, D. -M. (2012). Segmental liver hyperintensity in malignant biliary obstruction on diffusion weighted MRI: associated MRI findings and relationship with serum alanine aminotransferase levels. BRITISH JOURNAL OF RADIOLOGY, 85(1009), 22-28. doi:10.1259/bjr/24852804

Bhangu, A., Slesser, A., Brown, G., & Tekkis, P. (2012). Indications and outcomes of pelvic exenteration for locally advanced primary and recurrent rectal cancer. In BRITISH JOURNAL OF SURGERY Vol. 99 (pp. 70-71). Liverpool, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000306123100208&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Bhangu, A., Ali, M., Cunningham, D., Brown, G., & Tekkis, P. (2012). Comparison of long-term survival outcomes of operative versus non-operative management of recurrent rectal cancer. In BRITISH JOURNAL OF SURGERY Vol. 99 (pp. 95). Liverpool, ENGLAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000306123100284&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

2011

Hunter, C. J., Garant, A., Vuong, T., Artho, G., Lisbona, R., Tekkis, P., . . . Brown, G. (2012). Adverse Features on Rectal MRI Identify a High-risk Group that May Benefit from More Intensive Preoperative Staging and Treatment. ANNALS OF SURGICAL ONCOLOGY, 19(4), 1199-1205. doi:10.1245/s10434-011-2036-1

Pedersen, B. G., Moran, B., Brown, G., Blomqvist, L., Fenger-Gron, M., & Laurberg, S. (2011). Reproducibility of Depth of Extramural Tumor Spread and Distance to Circumferential Resection Margin at Rectal MRI: Enhancement of Clinical Guidelines for Neoadjuvant Therapy. AMERICAN JOURNAL OF ROENTGENOLOGY, 197(6), 1360-1366. doi:10.2214/AJR.11.6508

Shihab, O. C., Taylor, F., Bees, N., Blake, H., Jeyadevan, N., Bleehen, R., . . . Brown, G. (2011). Relevance of magnetic resonance imaging-detected pelvic sidewall lymph node involvement in rectal cancer. BRITISH JOURNAL OF SURGERY, 98(12), 1798-1804. doi:10.1002/bjs.7662

Shihab, O. C., Taylor, F., Salerno, G., Heald, R. J., Quirke, P., Moran, B. J., & Brown, G. (2011). MRI Predictive Factors for Long-Term Outcomes of Low Rectal Tumours. ANNALS OF SURGICAL ONCOLOGY, 18(12), 3278-3284. doi:10.1245/s10434-011-1776-2

Chand, M., & Brown, G. (2012). What are the relevant imaging factors to optimize treatment decisions?. In Multidisciplinary Management of Rectal Cancer: Questions and Answers (Vol. 9783642250057, pp. 27-39). doi:10.1007/978-3-642-25005-7_4

Evans, J., Tait, D., Swift, I., Pennert, K., Tekkis, P., Wotherspoon, A., . . . Brown, G. (2011). Timing of Surgery Following Preoperative Therapy in Rectal Cancer: The Need for a Prospective Randomized Trial?. DISEASES OF THE COLON & RECTUM, 54(10), 1251-1259. doi:10.1097/DCR.0b013e3182281f4b

Chua, S., Georgiou, P., Brown, G., Cook, G., Drake, B., Antoniou, A., & Tekkis, P. (2011). The added value of combined 18F-FDG PET-MRI in the preoperative assessment of local tumour invasion in recurrent and locally advanced primary rectal cancer using pelvic compartmental analysis. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 38, S194. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208619400368&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Chand, M., & Brown, G. (2012). How can we identify tumour penetration?. In Multidisciplinary Management of Rectal Cancer: Questions and Answers (Vol. 9783642250057, pp. 59-65). doi:10.1007/978-3-642-25005-7_7

Shihab, O. C., How, P., West, N., George, C., Patel, U., Quirke, P., . . . Brown, G. (2011). Can a Novel MRI Staging System for Low Rectal Cancer Aid Surgical Planning?. DISEASES OF THE COLON & RECTUM, 54(10), 1260-1264. doi:10.1097/DCR.0b013e31822abd78

Chua, S., Yu, S., Drake, B., Patel, U., Tait, D., Cook, G., . . . Brown, G. (2011). A prospective multicentre study to evaluate the diagnostic ability of multimodality imaging (FDG PET/CT, MRI and DW-MRI) in detecting early rectal tumour regrowth in cases of deferral of rectal surgery following continued response to preoperative chemoradiotherapy(CRT). EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 38, S157. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208619400236&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Brown, G. (2011). Commentary: MRI should not predict histopathological involved margins. COLORECTAL DISEASE, 13(9), 982-983. doi:10.1111/j.1463-1318.2011.02717.x

Wong, R., Cunningham, D., Barbachano, Y., Saffery, C., Valle, J., Hickish, T., . . . Chau, I. (2011). A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. ANNALS OF ONCOLOGY, 22(9), 2042-2048. doi:10.1093/annonc/mdq714

Patel, U. B., Taylor, F., Blomqvist, L., George, C., Evans, H., Tekkis, P., . . . Brown, G. (2011). Magnetic Resonance Imaging-Detected Tumor Response for Locally Advanced Rectal Cancer Predicts Survival Outcomes: MERCURY Experience. JOURNAL OF CLINICAL ONCOLOGY, 29(28), 3753-3760. doi:10.1200/JCO.2011.34.9068

Evans, J., Patel, U., & Brown, G. (2011). Rectal Cancer: Primary Staging and Assessment After Chemoradiotherapy. SEMINARS IN RADIATION ONCOLOGY, 21(3), 169-177. doi:10.1016/j.semradonc.2011.02.002

Hawkes, E. A., Cunningham, D., Tait, D., Brown, G., & Chau, I. (2011). Neoadjuvant Chemotherapy Alone for Early-Stage Rectal Cancer: An Evolving Paradigm?. SEMINARS IN RADIATION ONCOLOGY, 21(3), 196-202. doi:10.1016/j.semradonc.2011.02.005

Glimelius, B., Beets-Tan, R., Blomqvist, L., Brown, G., Nagtegaal, I., Pahlman, L., . . . van de Velde, C. (2011). Mesorectal Fascia Instead of Circumferential Resection Margin in Preoperative Staging of Rectal Cancer. JOURNAL OF CLINICAL ONCOLOGY, 29(16), 2142-2143. doi:10.1200/JCO.2010.34.4473

How, P., Shihab, O., Tekkis, P., Brown, G., Quirke, P., Heald, R., & Moran, B. (2011). A systematic review of cancer related patient outcomes after anterior resection and abdominoperineal excision for rectal cancer in the total mesorectal excision era. SURGICAL ONCOLOGY-OXFORD, 20(4), E149-E155. doi:10.1016/j.suronc.2011.05.001

Morton, D., Magill, L., Handley, K., Brown, G., Ferry, D. R., Gray, Z. B., . . . FOxTROT Collaborative Group. (2011). FOxTROT: Randomized phase II study of neoadjuvant chemotherapy (CT) with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer: Planned interim report.. J Clin Oncol, 29(15_suppl), 3568. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/28020286

Morton, D., Magill, L., Handley, K., Brown, G., Ferry, D. R., Gray, Z. B., . . . Gray, R. G. (2011). FOxTROT: Randomized phase II study of neoadjuvant chemotherapy (CT) with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer: Planned interim report. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. doi:10.1200/jco.2011.29.15_suppl.3568

Dewdney, A., Capdevila, J., Glimelius, B., Cervantes, A., Tait, D. M., Brown, G., . . . Cunningham, D. (2011). EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer.. J Clin Oncol, 29(15_suppl), 3513. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/28020332

Dewdney, A., Capdevila, J., Glimelius, B., Cervantes, A., Tait, D. M., Brown, G., . . . Cunningham, D. (2011). EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. doi:10.1200/jco.2011.29.15_suppl.3513

Taylor, F. G. M., Quirke, P., Heald, R. J., Moran, B., Blomqvist, L., Swift, I., . . . Brown, G. (2011). One millimetre is the safe cut-off for magnetic resonance imaging prediction of surgical margin status in rectal cancer. BRITISH JOURNAL OF SURGERY, 98(6), 872-879. doi:10.1002/bjs.7458

Taylor, F. G. M., Quirke, P., Heald, R. J., Moran, B., Blomqvist, L., Swift, I., . . . MERCURY study group. (2011). Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study.. Ann Surg, 253(4), 711-719. doi:10.1097/SLA.0b013e31820b8d52

Hunter, C., Garant, A., Vuong, T., Artho, G., Lisbona, R., Abulafi, M., & Brown, G. (2011). Potential therapeutic impact of routine pre-operative staging with FDG-PET/CT in high and low risk rectal cancer. In BRITISH JOURNAL OF SURGERY Vol. 98 (pp. 36). Royal Coll Surgery, Dublin, IRELAND: WILEY-BLACKWELL. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000290664500120&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Pedersen, B. G., Blomqvist, L., Brown, G., Fenger-Gron, M., Moran, B., & Laurberg, S. (2011). Postgraduate Multidisciplinary Development Program: Impact on the Interpretation of Pelvic MRI in Patients With Rectal Cancer: A Clinical Audit in West Denmark. DISEASES OF THE COLON & RECTUM, 54(3), 328-334. doi:10.1007/DCR.0b013e3182031e83

Georgiou, P. A., Tekkis, P. P., Patel, U., Antoniou, A., Darzi, A. W., Cunningham, D., . . . Brown, G. (2011). The added value of diffusion-weighted magnetic resonance imaging (DW-MRI) in the local staging of advanced colorectal pelvic cancer.. J Clin Oncol, 29(4_suppl), 378. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27985528

Georgiou, P. A., Tekkis, P. P., Patel, U., Antoniou, A., Darzi, A. W., Cunningham, D., . . . Brown, G. (2011). The added value of diffusion-weighted magnetic resonance imaging (DW-MRI) in the local staging of advanced colorectal pelvic cancer. JOURNAL OF CLINICAL ONCOLOGY, 29(4), 1 page. doi:10.1200/jco.2011.29.4_suppl.378

Hunter, C. J., Scurr, E., Jeyadevan, N., Collins, D. J., Abulafi, M., Tekkis, P. P., . . . Brown, G. (2011). Optimising magnetic resonance imaging for preoperative staging and surgical planning in colon cancer at 1.5 tesla and 3.0 tesla.. J Clin Oncol, 29(4_suppl), 395. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27985624

Hunter, C. J., Scurr, E., Jeyadevan, N., Collins, D. J., Abulafi, M., Tekkis, P. P., . . . Brown, G. (2011). Optimising magnetic resonance imaging for preoperative staging and surgical planning in colon cancer at 1.5 tesla and 3.0 tesla. JOURNAL OF CLINICAL ONCOLOGY, 29(4), 1 page. doi:10.1200/jco.2011.29.4_suppl.395

Dewdney, A., Cunningham, D., Tabernero, J., Glimelius, B., Cervantes, A., Tait, D. M., . . . Chau, I. (2011). EXPERT-C: A randomized phase II European multicenter trial of neoadjuvant chemotherapy (capecitabine/oxaliplatin) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined high-risk rectal cancer.. J Clin Oncol, 29(4_suppl), 360. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27985488

Dewdney, A., Cunningham, D., Tabernero, J., Glimelius, B., Cervantes, A., Tait, D. M., . . . Chau, I. (2011). EXPERT-C: A randomized phase II European multicenter trial of neoadjuvant chemotherapy (capecitabine/oxaliplatin) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined high-risk rectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 29(4), 1 page. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208847100358&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Tekkis, P. P., Georgiou, P. A., Constantinides, V. A., Patel, U., Antoniou, A., Goldin, R. D., . . . Brown, G. (2011). Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal pelvic cancer.. J Clin Oncol, 29(4_suppl), 370. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27985511

Tekkis, P. P., Georgiou, P. A., Constantinides, V. A., Patel, U., Antoniou, A., Goldin, R. D., . . . Brown, G. (2011). Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal pelvic cancer. JOURNAL OF CLINICAL ONCOLOGY, 29(4), 1 page. doi:10.1200/jco.2011.29.4_suppl.370

Yu, S. K., Brown, G., Heald, R. J., Chua, S., Cook, G., Barbachano, Y., . . . Tait, D. M. (2011). Deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (Watch and Wait) study: A phase II multicenter study in the United Kingdom.. J Clin Oncol, 29(4_suppl), 489. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27985501

Taylor, F. G. M., Quirke, P., Heald, R. J., Moran, B., Blomqvist, L., Swift, I., . . . Brown, G. (2011). Preoperative High-resolution Magnetic Resonance Imaging Can Identify Good Prognosis Stage I, II, and III Rectal Cancer Best Managed by Surgery Alone A Prospective, Multicenter, European Study. ANNALS OF SURGERY, 253(4), 711-719. doi:10.1097/SLA.0b013e31820b8d52

Georgiou, P. A., Tekkis, P. P., & Brown, G. (2011). Pelvic colorectal recurrence: crucial role of radiologists in oncologic and surgical treatment options.. Cancer Imaging, 11 Spec No A, S103-S111. doi:10.1102/1470-7330.2011.9025

2010

Shihab, O. C., Quirke, P., Heald, R. J., Moran, B. J., & Brown, G. (2010). Magnetic resonance imaging-detected lymph nodes close to the mesorectal fascia are rarely a cause of margin involvement after total mesorectal excision. BRITISH JOURNAL OF SURGERY, 97(9), 1431-1436. doi:10.1002/bjs.7116

Dighe, S., Purkayastha, S., Swift, I., Tekkis, P. P., Darzi, A., A’Hern, R., & Brown, G. (2010). Diagnostic precision of CT in local staging of colon cancers: a meta-analysis. CLINICAL RADIOLOGY, 65(9), 708-719. doi:10.1016/j.crad.2010.01.024

Dighe, S., Blake, H., Koh, M. -D., Swift, I., Arnaout, A., Temple, L., . . . Brown, G. (2010). Accuracy of multidetector computed tomography in identifying poor prognostic factors in colonic cancer. BRITISH JOURNAL OF SURGERY, 97(9), 1407-1415. doi:10.1002/bjs.7096

Koh, D. -M., George, C., Temple, L., Collins, D. J., Toomey, P., Raja, A., . . . Brown, G. (2010). Diagnostic Accuracy of Nodal Enhancement Pattern of Rectal Cancer at MRI Enhanced With Ultrasmall Superparamagnetic Iron Oxide: Findings in Pathologically Matched Mesorectal Lymph Nodes. AMERICAN JOURNAL OF ROENTGENOLOGY, 194(6), W505-W513. doi:10.2214/AJR.08.1819

Fernandez-Martos, C., Safont, M., Feliu, J., Pericay, C., Gallen, M., Vera, R., . . . Brown, G. (2010). Induction chemotherapy with or without chemoradiation in intermediate-risk rectal cancer patients defined by magnetic resonance imaging (MRI): A GEMCAD study. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. doi:10.1200/jco.2010.28.15_suppl.tps196

Gray, R. G., Morton, D., Brown, G., Ferry, D. R., Magill, L., Quirke, P., . . . Warren, B. (2010). FOxTROT: Randomized phase II study of neoadjuvant chemotherapy with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. doi:10.1200/jco.2010.28.15_suppl.tps192

Chua, Y. J., Barbachano, Y., Cunningham, D., Oates, J. R., Brown, G., Wotherspoon, A., . . . Chau, I. (2010). Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. LANCET ONCOLOGY, 11(3), 241-248. doi:10.1016/S1470-2045(09)70381-X

Georgiou, P., Tan, E., Gouvas, N., Antoniou, A., Brown, G., nicholls, R. J., & Tekkis, P. (2010). Lateral pelvic lymph-node dissection: still an option for cure Reply. LANCET ONCOLOGY, 11(2), 114-115. doi:10.1016/S1470-2045(10)70015-2

Watkins, D. J., Chau, I., Cunningham, D., Mudan, S. S., Karanjia, N., Brown, G., . . . Gillbanks, A. (2010). Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. BRITISH JOURNAL OF CANCER, 102(2), 255-261. doi:10.1038/sj.bjc.6605508

Taylor, F., Mangat, N., Swift, I. R., & Brown, G. (2010). Proforma-based reporting in rectal cancer.. Cancer Imaging, 10 Spec no A, S142-S150. doi:10.1102/1470-7330.2010.9092

Shihab, O. C., Brown, G., Daniels, I. R., Heald, R. J., Quirke, P., & Moran, B. J. (2010). Patients With Low Rectal Cancer Treated by Abdominoperineal Excision Have Worse Tumors and Higher Involved Margin Rates Compared With Patients Treated by Anterior Resection. DISEASES OF THE COLON & RECTUM, 53(1), 53-56. doi:10.1007/DCR.0b013e3181c70465

2009

Shihab, O. C., Heald, R. J., Rullier, E., Brown, G., Holm, T., Quirke, P., & Moran, B. J. (2009). Defining the surgical planes on MRI improves surgery for cancer of the low rectum. LANCET ONCOLOGY, 10(12), 1207-1211. doi:10.1016/S1470-2045(09)70084-1

Starling, N., Watkins, D., Cunningham, D., Thomas, J., Webb, J., Brown, G., . . . Chau, I. (2009). Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer. JOURNAL OF CLINICAL ONCOLOGY, 27(33), 5499-5505. doi:10.1200/JCO.2008.21.5384

Georgiou, P., Tan, E., Gouvas, N., Antoniou, A., Brown, G., Nicholls, R. J., & Tekkis, P. (2009). Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis. LANCET ONCOLOGY, 10(11), 1053-1062. doi:10.1016/S1470-2045(09)70224-4

Leary, A., Assersohn, L., Cunningham, D., Norman, A. R., Chong, G., Brown, G., . . . Oates, J. (2009). A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 64(3), 455-462. doi:10.1007/s00280-008-0893-5

O’Neill, B. D. P., Salerno, G., Thomas, K., Tait, D. M., & Brown, G. (2009). MR vs CT imaging: low rectal cancer tumour delineation for three-dimensional conformal radiotherapy. BRITISH JOURNAL OF RADIOLOGY, 82(978), 509-513. doi:10.1259/bjr/60198873

Starling, N., Okines, A., Cunningham, D., Allum, W., Wotherspoon, A., Benson, M., . . . Chau, I. (2009). A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. BRITISH JOURNAL OF CANCER, 100(11), 1725-1730. doi:10.1038/sj.bjc.6605070

Salerno, G. V., Daniels, I. R., Moran, B. J., Heald, R. J., Thomas, K., & Brown, G. (2009). Magnetic Resonance Imaging Prediction of an Involved Surgical Resection Margin in Low Rectal Cancer. DISEASES OF THE COLON & RECTUM, 52(4), 632-639. doi:10.1007/DCR.0b013e3181a0a37e

Shihab, O. C., Moran, B. J., Heald, R. J., Quirke, P., & Brown, G. (2009). MRI staging of low rectal cancer. EUROPEAN RADIOLOGY, 19(3), 643-650. doi:10.1007/s00330-008-1184-6

Potter, K. C., Husband, J. E., Houghton, S. L., Thomas, K., & Brown, G. (2009). Diagnostic Accuracy of Serial CT/Magnetic Resonance Imaging Review vs. Positron Emission Tomography/CT in Colorectal Cancer Patients with Suspected and Known Recurrence. DISEASES OF THE COLON & RECTUM, 52(2), 253-259. doi:10.1007/DCR.0b013e31819d11e6

Koh, D. -M., Brown, G., & Collins, D. J. (2009). Nanoparticles in rectal cancer imaging. CANCER BIOMARKERS, 5(2), 89-98. doi:10.3233/CBM-2009-0544

2008

Dighe, S., Swift, I., & Brown, G. (2008). CT staging of colon cancer. CLINICAL RADIOLOGY, 63(12), 1372-1379. doi:10.1016/j.crad.2008.04.021

Taylor, F. G. M., Swift, R. I., Blomqvist, L., & Brown, G. (2008). A Systematic Approach to the Interpretation of Preoperative Staging MRI for Rectal Cancer. AMERICAN JOURNAL OF ROENTGENOLOGY, 191(6), 1827-1835. doi:10.2214/AJR.08.1004

Smith, N. J., Shihab, O., Arnaout, A., Swift, R. I., & Brown, G. (2008). MRI for Detection of Extramural Vascular Invasion in Rectal Cancer. AMERICAN JOURNAL OF ROENTGENOLOGY, 191(5), 1517-1522. doi:10.2214/AJR.08.1298

Salerno, G., Chandler, I., Wotherspoon, A., Thomas, K., Moran, B., & Brown, G. (2008). Sites of surgical waisting in the abdominoperineal specimen. BRITISH JOURNAL OF SURGERY, 95(9), 1147-1154. doi:10.1002/bjs.6231

Brown, G. (2008). MRI: STAGING AND RE-STAGING AFTER PREOPERATIVE TREATMENT, NEW CONTRAST AGENTS. In RADIOTHERAPY AND ONCOLOGY Vol. 88 (pp. S128). ELSEVIER IRELAND LTD. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000433281200354&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

ONeill, B., Tait, D., & Brown, G. (2008). ANASTOMOTIC LOCAL RECURRENCE OF RECTAL CANCER REMAINS AN IMPORTANT AND PREVENTABLE PATTERN OF FAILURE FOLLOWING TOTAL MESORECTAL EXCISION: LESSONS FOR RADIOTHERAPISTS. In RADIOTHERAPY AND ONCOLOGY Vol. 88 (pp. S87). ELSEVIER IRELAND LTD. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000433281200248&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Kong, G., Jackson, C., Koh, D. M., Lewington, V., Sharma, B., Brown, G., . . . Cook, G. J. R. (2008). The use of F-18-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 35(7), 1323-1329. doi:10.1007/s00259-008-0743-z

Koh, D. -M., Chau, I., Tait, D., Wotherspoon, A., Cunningham, D., & Brown, G. (2008). Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 71(2), 456-461. doi:10.1016/j.ijrobp.2007.10.016

Koh, D. M., Brown, G., Riddell, A. M., Scurr, E., Collins, D. J., Allen, S. D., . . . Husband, J. E. (2008). Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. EUROPEAN RADIOLOGY, 18(5), 903-910. doi:10.1007/s00330-007-0847-z

Moran, B., Brown, G., Cunningham, D., Daniels, I., Heald, R., Quirke, P., & Sebag-Montefiore, D. (2008). Clarifying the TNM staging of rectal cancer in the context of modern imaging and neo-adjuvant treatment: ‘y”u’ and ‘p’ need ‘mr’ and ‘ct’. COLORECTAL DISEASE, 10(3), 242-243. doi:10.1111/j.1463-1318.2007.01260.x

Smith, N. J., Barbachano, Y., Norman, A. R., Swift, R. I., Abulafi, A. M., & Brown, G. (2008). Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. BRITISH JOURNAL OF SURGERY, 95(2), 229-236. doi:10.1002/bjs.5917

Koh, D. M., Dzik-Jurasz, A., O’Neill, B., Tait, D., Husband, J. E., & Brown, G. (2008). Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. BRITISH JOURNAL OF RADIOLOGY, 81(962), 91-98. doi:10.1259/bjr/96187638

Park, S. H. (2008). Degree of error of thin-section MR in measuring extramural depth of tumor invasion in patients with rectal cancer.. Radiology, 246(2), 647. doi:10.1148/radiol.2462070843

Brown, G., & Norman, A. R. (2008). Degree of error of thin-section MR in measuring extramural depth of tumor invasion in patients with rectal cancer – Response. RADIOLOGY, 246(2), 648. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000252796300049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Koh, D. -M., Smith, N. J., Swift, R. I., & Brown, G. (2008). The Relationship Between MR Demonstration of Extramural Venous Invasion and Nodal Disease in Rectal Cancer.. Clin Med Oncol, 2, 267-273. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21892288

O’Neill, B., Brown, G., Wotherspoon, A., Burton, S., Norman, A., & Tait, D. (2008). Successful downstaging of high rectal and recto-sigmoid cancer by neo-adjuvant chemo-radiotherapy.. Clin Med Oncol, 2, 135-144. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21892276

Brown, G. (2008). Staging rectal cancer: endoscopic ultrasound and pelvic MRI.. Cancer Imaging, 8 Spec No A, S43-S45. doi:10.1102/1470-7330.2008.9008

Smith, N., & Brown, G. (2008). Preoperative staging of rectal cancer. ACTA ONCOLOGICA, 47(1), 20-31. doi:10.1080/02841860701697720

O’Neill, B. D. P., Tait, D. M., & Brown, G. (2008). Anastomotic local recurrence of rectal cancer remains an important and preventable pattern of failure following total mesorectal excision: Lessons for radiotherapists. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 72 (pp. S246). Boston, MA: ELSEVIER SCIENCE INC. doi:10.1016/j.ijrobp.2008.06.635

Burton, S., Brown, G., Bees, N., Norman, A., Biedrzycki, O., Arnaout, A., . . . Swift, R. I. (2008). Accuracy of CT prediction of poor prognostic features in colonic cancer. BRITISH JOURNAL OF RADIOLOGY, 81(961), 10-19. doi:10.1259/bjr/19492531

2007

O’Neill, B. D. P., Brown, G., Cunningham, D., Heald, R. J., & Tait, D. M. (2007). Chemoradiotherapy alone for rectal cancer: A word of caution – Reply. LANCET ONCOLOGY, 8(10), 862-863. doi:10.1016/S1470-2045(07)70293-0

O’Neill, B., Chaldecott, R., Brown, G., Sharma, R. A., Norman, A., Scurr, E., . . . Tait, D. M. (2007). Optimisation of radiotherapy planning for rectal cancer: a comparison of supine CT and MRI defined target and normal tissue dose volume data. In EJC SUPPLEMENTS Vol. 5 (pp. 258). Barcelona, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD. doi:10.1016/S1359-6349(07)71001-7

Brown, G. (2007). Imaging of liver metastases (CT scan, MRI, PET scan). EJC SUPPLEMENTS, 5(5), 297-300. doi:10.1016/S1359-6349(07)70056-3

O’Neill, B. D. P., Brown, G., Heald, R. J., Cunningham, D., & Tait, D. M. (2007). Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. LANCET ONCOLOGY, 8(7), 625-633. doi:10.1016/S1470-2045(07)70202-4

Watkins, D. J., Jackson, C., Chua, Y., Chong, G., Norman, A. R., Brown, G., . . . Cunningham, D. (2007). A prospective study of oxaliplatin and capecitabine (CapOx) in metastatic colorectal cancer (MCRC) with baseline stratification according to resectability status. In JOURNAL OF CLINICAL ONCOLOGY Vol. 25 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000455043700678&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Salerno, G., Daniels, I. R., Brown, G., Norman, A. R., Moran, B. J., & Heald, R. J. (2007). Variations in pelvic dimensions do not predict the risk of circumferential resection margin (CRM) involvement in rectal cancer. WORLD JOURNAL OF SURGERY, 31(6), 1313-1320. doi:10.1007/s00268-007-9007-5

Smith, N. J., Bees, N., Barbachano, Y., Norman, A. R., Swift, R. I., & Brown, G. (2007). Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials. BRITISH JOURNAL OF CANCER, 96(7), 1030-1036. doi:10.1038/sj.bjc.6603646

Fowler, J. M., Beagley, C. E., Blomqvist, L., Brown, G., Daniels, I. R., Heald, R. J., . . . Sebag-Montefiore, D. (2007). Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: Results of the MERCURY Study. RADIOLOGY, 243(1), 132-139. doi:10.1148/radiol.2431051825

Riddell, A. M., Allum, W. H., Thompson, J. N., Wotherspoon, A. C., Richardson, C., & Brown, G. (2007). The appearances of oesophageal carcinoma demonstrated on high-resolution, T2-weighted MRI, with histopathological correlation. EUROPEAN RADIOLOGY, 17(2), 391-399. doi:10.1007/s00330-006-0363-6

Koh, D. -M., Brown, G., Meer, Z., Norman, A. R., & Husband, J. E. (2007). Diagnostic accuracy of rim and segmental MRI enhancement of colorectal hepatic metastasis after administration of mangafodipir trisodium. AMERICAN JOURNAL OF ROENTGENOLOGY, 188(2), W154-W161. doi:10.2214/AJR.05.1421

Starling, N., & Brown, G. (2007). Patterns of recurrence following therapy for rectal cancer. In Colorectal Cancer (pp. 233-247). doi:10.1017/CBO9780511902468.013

Burton, S., & Brown, G. (2007). MRI staging. In Colorectal Cancer (pp. 174-211). doi:10.1017/CBO9780511902468.011

Brown, G. (2007). Imaging of metastatic disease. In Colorectal Cancer (pp. 212-232). doi:10.1017/CBO9780511902468.012

Riddell, A. M., Davies, D. C., Allum, W. H., Wotherspoon, A. C., Richardson, C., & Brown, G. (2007). High-resolution MRI in evaluation of the surgical anatomy of the esophagus and posterior mediastinum. AMERICAN JOURNAL OF ROENTGENOLOGY, 188(1), W37-W43. doi:10.2214/AJR.05.1795

Burton, S., & Brown, G. (2007). CT staging. In Colorectal Cancer (pp. 157-173). doi:10.1017/CBO9780511902468.010

Brown, G., Reznek, R. H., & Husband, J. E. (2007). Colorectal cancer. doi:10.1017/CBO9780511902468

2006

Petroudi, S., Brown, G., Bond, S., & Brady, M. (2006). Circumferential resection margin assessment on MRI of rectal cancer.. Conference proceedings : … Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference, 4881-4884.

Riddell, A. M., Richardson, C., Scurr, E., & Brown, G. (2006). The development and optimization of high spatial resolution Mill for imaging the oesophagus using an external surface coil. BRITISH JOURNAL OF RADIOLOGY, 79(947), 873-879. doi:10.1259/bjr/36989440

Riddell, A. M., Hillier, J., Brown, G., King, D. M., Wotherspoon, A. C., Thompson, J. N., . . . Allum, W. H. (2006). Potential of surface-coil MRI for staging of esophageal cancer. AMERICAN JOURNAL OF ROENTGENOLOGY, 187(5), 1280-1287. doi:10.2214/AJR.05.0559

Koh, D. M., Brown, G., & Husband, J. E. (2006). Nodal staging in rectal cancer. ABDOMINAL IMAGING, 31(6), 652-659. doi:10.1007/s00261-006-9021-3

Salerno, G., Daniels, I. R., Brown, G., Heald, R. J., & Moran, B. J. (2006). Magnetic resonance imaging pelvimetry in 186 patients with rectal cancer confirms an overlap in pelvic size between males and females. COLORECTAL DISEASE, 8(9), 772-776. doi:10.1111/j.1463-1318.2006.01090.x

Salerno, G., Daniels, I. R., Moran, B. J., Wotherspoon, A., & Brown, G. (2006). Clarifying margins in the multidisciplinary management of rectal cancer: the MERCURY experience. CLINICAL RADIOLOGY, 61(11), 916-923. doi:10.1016/j.crad.2006.06.005

Heald, R. J., O’Neill, B. D. P., Moran, B., Brown, G., Darzi, A. W., Wotherspoon, A. C., . . . Tait, D. M. (2006). MRI in predicting curative resection of rectal cancer – New dilemma in multidisciplinary team management. BMJ-BRITISH MEDICAL JOURNAL, 333(7572), 808. doi:10.1136/bmj.333.7572.808

Brown, G., Daniels, I. R., Heald, R. J., Quirke, P., Blomqvist, L., Sebag-Montefiore, D., . . . Mason, B. (2006). Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BRITISH MEDICAL JOURNAL, 333(7572), 779-782. doi:10.1136/bmj.38937.646400.55

Chau, I., Cunningham, D., Tait, D., & Brown, G. (2006). Role of neoadjuvant chemotherapy in rectal cancer: Interpretation of the EXPERT study – Reply. JOURNAL OF CLINICAL ONCOLOGY, 24(28), 4665-4666. doi:10.1200/JCO.2006.08.2206

Salerno, G., Daniels, I. R., & Brown, G. (2006). Magnetic resonance imaging of the low rectum: defining the radiological anatomy. COLORECTAL DISEASE, 8, 10-13. doi:10.1111/j.1463-1318.2006.01063.x

Daniels, I. R., Fisher, S. E., Brown, G., Heald, R. J., & Moran, B. J. (2006). Complexities and controversies in the management of low rectal cancer: Proceedings of the 3rd Pelican Surgical Symposium 2005. COLORECTAL DISEASE, 8, 3-4. doi:10.1111/j.1463-1318.2006.01061.x

Koh, D. M., Scurr, E., Collins, D. J., Pirgon, A., Kanber, B., Karanjia, N., . . . Husband, J. E. (2006). Colorectal hepatic metastases: quantitative measurements using single-shot echo-planar diffusion-weighted MR imaging. EUROPEAN RADIOLOGY, 16(9), 1898-1905. doi:10.1007/s00330-006-0201-x

Burton, S., Norman, A. R., Brown, G., Abulafi, A. M., & Swift, R. I. (2006). Predictive poor prognostic factors in colonic carcinoma. SURGICAL ONCOLOGY-OXFORD, 15(2), 71-78. doi:10.1016/j.suronc.2006.08.003

Chong, G., Starling, N., Norman, A. R., Brown, G., Thomas, J., Ross, P. J., & Cunningham, D. C. (2006). Phase II study of fixed dose rate gemcitabine in patients with pretreated advanced colorectal cancer.. J Clin Oncol, 24(18_suppl), 13558. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27952203

Rutten, H., Sebag-Montefiore, D., Glynne-Jones, R., Rullier, E., Peeters, M., Brown, G., . . . Quirke, P. (2006). Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 24 (pp. 153S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239009401046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Pitt-Francis, J., Chen, D., Slaymaker, M., Simpson, A., Brady, M., van Leeuwen, I., . . . Gavaghan, D. (2006). Multimodal imaging techniques for the extraction of detailed geometrical and physiological information for use in multi-scale models of colorectal cancer and treatment of individual patients. Computational and Mathematical Methods in Medicine, 7(2-3), 177-188. doi:10.1080/10273660600969083

Burton, S., Brown, G., Daniels, I., Norman, A., Swift, I., Abulafi, M., . . . Tait, D. (2006). MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: Treatment with radiotherapy and chemotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 65(2), 445-451. doi:10.1016/j.ijrobp.2005.12.027

Burton, S., Brown, G., Daniels, I. R., Norman, A. R., Mason, B., & Cunningham, D. (2006). MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?. BRITISH JOURNAL OF CANCER, 94(3), 351-357. doi:10.1038/sj.bjc.6602947

Chan, I., Brown, G., Cunningham, D., Tait, D., Wotherspoon, A., Norman, A. R., . . . Oates, J. (2006). Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 24(4), 668-674. doi:10.1200/JCO.2005.04.4875

Riddell, A., Allum, W., Thompson, J., Wotherspoon, A., Cunningham, D., & Brown, G. (2006). The impact of high resolution MRI for determining operability of esophageal cancer. In ANNALS OF ONCOLOGY Vol. 17 (pp. 90). Barcelona, SPAIN: OXFORD UNIV PRESS. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239782000282&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

O’Neill, B. D. P., Brown, G., & Tait, D. M. (2006). Successful downstaging of upper rectal and distal sigmoid tumours by preoperative chemo-radiotherapy. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 66 (pp. S302). Philadelphia, PA: ELSEVIER SCIENCE INC. doi:10.1016/j.ijrobp.2006.07.570

Smith, N., Norman, A., Swift, I., & Brown, G. (2006). MRI detects extra-mural vascular invasion and predicts outcome in colorectal cancer. In ANNALS OF ONCOLOGY Vol. 17 (pp. 24-25). Barcelona, SPAIN: OXFORD UNIV PRESS. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239782000022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Salerno, G., Daniels, I., & Brown, G. (2006). Low rectal cancers at the intersphincteric plane are at high risk of close resection margins: An analysis of the mercury study MRI scans. In ANNALS OF ONCOLOGY Vol. 17 (pp. 45-46). Barcelona, SPAIN: OXFORD UNIV PRESS. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239782000102&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Petroudi, S., Brown, G., Bond, S., & Brady, M. (2006). Circumferential resection margin assessment on MRI of rectal cancer.. Conf Proc IEEE Eng Med Biol Soc, 1, 4881-4884. doi:10.1109/IEMBS.2006.259277

Petroudi, S., Brown, G., Bond, S., & Brady, M. (2006). Circumferential resection margin assessment on MRI of rectal cancer. In 2006 28TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-15 (pp. 3851-+). New York, NY: IEEE. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000247284704116&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

2005

Brown, G., & Zbar, A. P. (2005). MRI in colorectal surgery: Surface magnetic resonance imaging in anorectal practice. In Complex Anorectal Disorders: Investigation and Management (pp. 275-297). doi:10.1007/1-84628-057-5_17

Sebag-Montefiore, D., Brown, G., Rutten, H., Rullier, E., Peeters, M., Glynne-Jones, R., . . . Van de Velde, C. (2005). An international phase II study of Capecitabine, Oxaliplatin, Radiotherapy and Excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma. Interim results. EJC SUPPLEMENTS, 3(2), 170. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000247564800586&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Koh, D. M., Brown, G., Temple, L., Blake, H., Raja, A., Toomey, P., . . . Husband, J. E. (2005). Distribution of mesorectal lymph nodes in rectal cancer: in vivo MR imaging compared with histopathological examination. Initial observations. EUROPEAN RADIOLOGY, 15(8), 1650-1657. doi:10.1007/s00330-005-2751-8

Assersohn, L., Norman, A. R., Chong, G., Brown, G., Ross, P. J., Costello, C., . . . Cunningham, D. (2005). Phase II trial evaluating capecitabine and irinotecan in patients (pts) with esophago-gastric (E-G) carcinoma having progressed or relapsed within 3 months of platinum-based chemotherapy.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 350S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000230326602221&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Starling, N., Brown, G., Tait, D., Norman, A., & Cunningham, D. (2005). Patterns of pelvic recurrence in patients with rectal cancers treated with adjuvant chemotherapy in a multicentre randomised study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 271S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000230326601496&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Brown, G., Daniels, I. R., Richardson, C., Revell, P., Peppercorn, D., & Bourne, M. (2005). Techniques and trouble-shooting in high spatial resolution thin slice MRI for rectal cancer. BRITISH JOURNAL OF RADIOLOGY, 78(927), 245-251. doi:10.1259/bjr/33540239

Brown, G., Daniels, I. R., & Quirke, P. (2005). MRI predicts surgical resection margin status in patients with rectal cancer. – Results from the MERCURY study group. In JOURNAL OF PATHOLOGY Vol. 205 (pp. 13). London, ENGLAND: JOHN WILEY & SONS LTD. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000227614000051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Daniels, I. R., Brown, G., & Quirke, P. (2005). High spatial resolution MRI predicts tumour spread in patients with rectal cancer – Results from the MERCURY study group. In JOURNAL OF PATHOLOGY Vol. 205 (pp. 13). London, ENGLAND: JOHN WILEY & SONS LTD. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000227614000053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Brown, G. (2005). Thin section MRI in multidisciplinary pre-operative decision making for patients with rectal cancer. BRITISH JOURNAL OF RADIOLOGY, 78, S117-S127. doi:10.1259/bjr/15128198

Brown, G., & Daniels, I. R. (2005). Preoperative staging of rectal cancer: the MERCURY research project.. Recent Results Cancer Res, 165, 58-74. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15865021

2004

Salerno, G., Daniels, I., Heald, R. J., Brown, G., & Moran, B. J. (2004). Management and imaging of low rectal carcinoma. SURGICAL ONCOLOGY-OXFORD, 13(2-3), 55-61. doi:10.1016/j.suronc.2004.09.013

Burton, S., Daniels, I., Brown, G., Stellakis, M., Chau, I., Swift, I. R., . . . Cunningham, D. (2004). Evaluation of the role of MRI in staging rectal cancer within the multidisciplinary team setting.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 22 (pp. 272S). New Orleans, LA: AMER SOC CLINICAL ONCOLOGY. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000223512401079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Brown, G., Davies, S., Williams, G. T., Bourne, M. W., Newcombe, R. G., Radcliffe, A. G., . . . Maughan, T. S. (2004). Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging?. BRITISH JOURNAL OF CANCER, 91(1), 23-29. doi:10.1038/sj.bjc.6601871

Salerno, G., Daniels, I., Croxford, M., Brown, G., & Heald, R. J. (2004). Preoperative radiotherapy for rectal cancer. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 97(7), 361-362. doi:10.1258/jrsm.97.7.361-b

Blomqvist, L. (2004). Colorectal cancer imaging. AMERICAN JOURNAL OF ROENTGENOLOGY, 182(6), 1600-1601. doi:10.2214/ajr.182.6.1821600a

Chau, I., Allen, M. J., Cunningham, D., Norman, A. R., Brown, G., Ford, H. E. R., . . . Oates, J. (2004). The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 22(8), 1420-1429. doi:10.1200/JCO.2004.05.041

Koh, D. M., Brown, G., Temple, L., Raja, A., Toomey, P., Bett, N., . . . Husband, J. E. (2004). Rectal cancer: Mesorectal lymph nodes at MR Imaging with USPIO versus histopathologic findings – Initial observations. RADIOLOGY, 231(1), 91-99. doi:10.1148/radiol.2311030142

Brown, G. (2004). Local radiological staging of rectal cancer. CLINICAL RADIOLOGY, 59(3), 213-214. doi:10.1016/j.crad.2003.10.001

Snelling, J. D., Abdullah, N., Brown, G., King, D. M., Moskovic, E., & Gui, G. P. H. (2004). Measurement of tumour size in case selection for breast cancer therapy by clinical assessment and ultrasound. EJSO, 30(1), 5-9. doi:10.1016/j.ejso.2003.10.003

Brown, G., Kirkham, A., Williams, G. T., Bourne, M., Radcliffe, A. G., Sayman, J., . . . Heald, R. J. (2004). High-resolution MRI of the anatomy important in total mesorectal excision of the rectum. AMERICAN JOURNAL OF ROENTGENOLOGY, 182(2), 431-439. doi:10.2214/ajr.182.2.1820431

Assersohn, L., Brown, G., Cunningham, D., Ward, C., Oates, J., Waters, J. S., . . . Norman, A. R. (2004). Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. ANNALS OF ONCOLOGY, 15(1), 64-69. doi:10.1093/annonc/mdh007

Heald, R. J., Moran, B. J., Brown, G., & Daniels, I. R. (2004). Optimal total mesorectal excision for rectal cancer is by dissection in front of Denonvilliers’ fascia. BRITISH JOURNAL OF SURGERY, 91(1), 121-123. doi:10.1002/bjs.4386

2003

Brown, G. (2003). Imaging of the liver in metastatic disease. EJC SUPPLEMENTS, 1(6), 159-171. doi:10.1016/S1359-6349(03)90020-6

Chau, I., Cunningham, D., Tait, D., Brown, G., Tebbutt, N., Hill, M., . . . Massey, A. (2003). Twelve weeks of neoadjuvant capecitabine (cap) and oxaliplatin (ox) followed by synchronous chemoradiation (CRT) and total mesorectal excision (TME) in MRI defined poor risk locally advanced rectal cancer resulted in promising tumour regression and rapid symptomatic relief. In BRITISH JOURNAL OF CANCER Vol. 88 (pp. S20). BOURNEMOUTH, ENGLAND: NATURE PUBLISHING GROUP. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000184042200075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Brown, G., Richards, C. J., Bourne, M. W., Newcombe, R. G., Radcliffe, A. G., Dallimore, N. S., & Williams, G. T. (2003). Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. RADIOLOGY, 227(2), 371-377. doi:10.1148/radiol.2272011747

Chau, I., Allen, M., Cunningham, D., Tait, D., Brown, G., Hill, M., . . . Prior, Y. (2003). Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. BRITISH JOURNAL OF CANCER, 88(7), 1017-1024. doi:10.1038/sj.bjc.6600822

Brown, G., Radcliffe, A. G., Newcombe, R. G., Dallimore, N. S., Bourne, M. W., & Williams, G. T. (2003). Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. BRITISH JOURNAL OF SURGERY, 90(3), 355-364. doi:10.1002/bjs.4034

Chau, I., Kelleher, M. T., Cunningham, D., Norman, A. R., Wotherspoon, A., Trott, P., . . . Bishop, L. (2003). Rapid access multidisciplinary lymph node diagnostic clinic: analysis of 550 patients. BRITISH JOURNAL OF CANCER, 88(3), 354-361. doi:10.1038/sj.bjc.6600738

2002

Brown, G., Drury, A. E., Cunningham, D., & Husband, J. E. S. (2003). CT detection of hydronephrosis in resected colorectal cancer: a predictor of recurrent disease. CLINICAL RADIOLOGY, 58(2), 137-142. doi:10.1053/crad.2002.1123

Tan, S. M., Behranwala, K. A., Trott, P. A., Nasim, N. A., Moskovic, E., Brown, G., . . . Gui, G. P. H. (2002). Erratum: A retrospective study comparing the individual modalities of triple assessment in the pre-operative diagnosis of invasive lobular breast carcinoma (European Journal of Surgical Oncology (2002) vol. 28 (203-8)). European Journal of Surgical Oncology, 28(8), 900. doi:10.1053/ejso.2002.1368

Bartram, C., & Brown, G. (2002). Endorectal ultrasound and magnetic resonance imaging in rectal cancer staging. GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 31(3), 827-+. doi:10.1016/S0889-8553(02)00027-4

Dzik-Jurasz, A., Domenig, C., George, M., Wolber, J., Padhani, A., Brown, G., & Doran, S. (2002). Diffusion MRI for prediction of response of rectal cancer to chemoradiation. LANCET, 360(9329), 307-308. doi:10.1016/S0140-6736(02)09520-X

Tan, S. M., Behranwala, K. A., Trott, P. A., Nasim, N. A., Moskovic, E., Brown, G., . . . Gui, G. P. H. (2002). A retrospective study comparing the individual modalities of triple assessment in the pre-operative diagnosis of invasive lobular breast carcinoma. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 28(3), 203-208. doi:10.1053/ejso.2001.1236

2001

Tan, S. M., Behranwala, K. A., Nasiri, N., Trott, P. A., King, D. M., Moskovic, E., . . . Gui, G. P. H. (2001). Triple assessment in the preoperative diagnosis of invasive tabular breast carcinoma: A comparison of the individual modalities. Breast Cancer Research and Treatment, 69(3), 297.

Whitehouse, P. A., Barber, Y., Brown, G., Moskovic, E., King, D. M., & Gui, G. P. H. (2001). Office ultrasound by breast surgeons: A rapid, accurate adjunct to clinical diagnosis. Breast Cancer Research and Treatment, 69(3), 237.

George, M. L., Dzik-Jurasz, A. S. K., Padhani, A. R., Brown, G., Tait, D. M., Eccles, S. A., & Swift, R. I. (2001). Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. BRITISH JOURNAL OF SURGERY, 88(12), 1628-1636. doi:10.1046/j.0007-1323.2001.01947.x

George, M. L., Dzik-Jurasz, A. S. K., Brown, G., Padhani, A. R., Husband, J., Leach, M. O., . . . Swift, R. I. (2001). Dynamic contrast MRI (DCMRI) assessment of tumour permeability in locally advanced rectal cancer: a prognostic indicator for response to chemoradiotherapy. BRITISH JOURNAL OF SURGERY, 88, 25. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000168603000077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Radcliffe, A., & Brown, G. (2001). Will MRI provide maps of lines of excision for rectal cancer?. LANCET, 357(9255), 495-496. doi:10.1016/S0140-6736(00)04038-1

Whitehouse, P. A., Baber, Y., Brown, G., Moskovic, E., King, D. M., & Gui, G. P. H. (2001). The use of ultrasound by breast surgeons in outpatients: an accurate extension of clinical diagnosis. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 27(7), 611-616. doi:10.1053/ejso.2001.1201

2000

Brown, G. (2000). The role of MRI in the local staging of rectal cancer. In Cancer Imaging Vol. 1 (pp. 7-10).

Brown, G. (2000). CT patterns of recurrent disease in colorectal cancer. In Cancer Imaging Vol. 1 (pp. 14-17).

Brown, G. (2000). The role of MRI in the pre-operative staging of rectal cancer. Imaging, 12(2), 141-150. doi:10.1259/img.12.2.120141

1999

Brown, G., Richards, C. J., Newcombe, R. G., Dallimore, N. S., Radcliffe, A. G., Carey, D. P., . . . Williams, G. T. (1999). Rectal carcinoma: Thin-section MR imaging for staging in 28 patients. RADIOLOGY, 211(1), 215-222. doi:10.1148/radiology.211.1.r99ap35215

Brown, G., Phillips, S., Cochlin, D., Bourne, M. W., & Jenkins, B. (1997). Dynamic magnetic resonance imaging of the testis: Preliminary results. British Journal of Urology, 79(SUPPL. 4), 20.

BROWN, G., & SHAW, D. G. (1995). INFLAMMATORY PSEUDOTUMORS IN CHILDREN – CT AND ULTRASOUND APPEARANCES WITH HISTOPATHOLOGICAL CORRELATION. CLINICAL RADIOLOGY, 50(11), 782-786. doi:10.1016/S0009-9260(05)83220-9

BROWN, G., MACVICAR, D. A., AYTON, V., & HUSBAND, J. E. (1995). THE ROLE OF INTRAVENOUS CONTRAST ENHANCEMENT IN MAGNETIC-RESONANCE-IMAGING OF PROSTATIC-CARCINOMA. CLINICAL RADIOLOGY, 50(9), 601-606. doi:10.1016/S0009-9260(05)83288-X

Schon, F., Brown, G., & Britton, J. (1995). Tuberculous myelopathy: a serial MRI study.. J Neurol Neurosurg Psychiatry, 58(2), 259-260. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/7876874

BROWN, G., WARREN, M., WILLIAMS, J. E., ADAM, E. J., & COLES, J. A. (1993). CRANIAL COMPUTED-TOMOGRAPHY OF ELDERLY PATIENTS – AN EVALUATION OF ITS USE IN ACUTE NEUROLOGICAL PRESENTATIONS. AGE AND AGEING, 22(4), 240-243. doi:10.1093/ageing/22.4.240

BROWN, G., & HUSBAND, J. E. (1993). MEDIASTINAL WIDENING – A VALUABLE RADIOGRAPHIC SIGN OF SUPERIOR VENA-CAVA THROMBOSIS. CLINICAL RADIOLOGY, 47(6), 415-420. doi:10.1016/S0009-9260(05)81063-3

МРТ рака прямой кишки

5 февраля 2020

Продано!

Адрес: Доброслободская 5, Москва (после регистрации вы получите email с подробной информацией о месте проведения)

sb pic 2 to load Доктор Светлана Балясникова, старший преподаватель Imperial College London, к.м.н., врач-рентгенолог The Royal Marsden Hospital с 2013 года, работающий под руководством Проф. Джины Браун, на примере клинических случаев проведет детальный разбор современных аспектов и методов МР-диагностики рака прямой кишки. Уникальность Курса заключается в возможности участников самостоятельно разобрать реальные клинические случаи на индивидуальных рабочих станциях под руководством доктора Балясниковой, задать вопросы и получить детальные пояснения. Участников также ждет прямое видео включение из Лондона, во время которого Проф.

Джина Браун расскажет о современных методах стратификации пациентов и подходах в лечении рака прямой кишки в зависимости от стадии заболевания. В течение дня буд both pic 2 to load ут подробно разобраны вопросы диагностики, стадирования и оценки эффективности лечения местно-распространенных форм рака, определения резектабельности и диагностики рецидивов. По окончанию курса слушателей получат электронный буклет со всеми презентациями и наиболее информативными клиническими случаями. Также полезным бонусом для слушателей курса будет получение сертификата Британского Королевского Колледжа Рентгенологов (The Royal College of Radiologists).

при поддержке «Российского общества специалистов по колоректальному раку» и «НМИЦ онкологии им.Н.Н.Блохина»

Due to open

Please click on trial you wish to know more about

PRESERVE

Closed to recruitment

Please click on the trial you wish to know more about

6 vs 12

Deferral of Surgery

MARVEL

MERCURY II

SOPRANO

Meetings

Future Horizons 6th International Colorectal Symposium

Monday 22nd September 2025

PRESERVE Early Rectal Cancer Meeting

Friday 15th
March 2024

Achieving Successful Frontline Clinical Research in a DGH

Celebrating 20 Years of Patient Focused Research at Croydon University Hospital

The DGH environment is a perfect space to do excellent clinical research. Please join us and be part of the collaboration to build a future in research together!

Wednesday 10th November 2021

Royal Society of Medicine, 1 Wimpole Street

PROGRAMME

09:00 – 09:30 Registration

09:30 – 09:40 Welcome Muti Abulafi, Ian Swift, London UK

09:40 – 09:50 Croydon Research and its benefits to the NHS Matthew Kershaw, Chief Executive, Croydon Health Services NHS Trust

09:45 – 10:00 Roll of honour: fellows, funders and supporters Gina Brown, London UK

10:00 – 11:10 Setting the standards: Croydon leading the way in colon cancer research

Highlighting the work of: Andrew Beggs; Shwetal Dighe; Vera Tudyka; Sarah Burton; Chris Hunter; Nigel D’Souza; Neil Smith; Nigel Day; Richard Booth

10:50 Expert Panel commentary with audience discussion and voting

11:10 – 11:35 Morning Coffee

11:35 – 12:45 Saving the rectum: precision imaging directing precision surgery

Highlighting the work of: Matt Tutton; Annabel Shaw; James Read; Rachel Carten

10:50 Expert Panel commentary with audience discussion and voting

12:45 – 13:30 Lunch

13:30 – 14:40 Discovering actual pathways of spread: challenging Dukes’ classification in bowel cancer

Highlighting the work of: Andrew Beggs; Neil Smith; Amy Lord; Fiona Taylor; Manish Chand; Nigel D’Souza; Mohammed Siddiqui

14:20 Expert Panel commentary with audience discussion and voting

14:40 – 15:00 Afternoon tea

15:00 – 15:45 Timing is everything: when and if to operate after radiotherapy

Highlighting the work of: Mark George; Jess Evans; Svetlana Balyasnikova; Fiona Taylor; Jemma Bhoday

15:40 Expert Panel commentary with audience discussion and voting

15:45 – 16:45 Is there still a place for frontline research in the DGH setting? Expert Panel commentary with audience discussion and voting

16:45 – 17:00 Closing Remarks Neil Mortensen, Oxford UK

Please fill in the form below to register your place

Privacy Policy

Who we are

Our website address is: https://profginabrown.com.

What personal data we collect and why we collect it

Contact forms

We only retain collected information for as long as necessary to provide you with your requested service. What data we store, we’ll protect within commercially acceptable means to prevent loss and theft, as well as unauthorised access, disclosure, copying, use or modification.

Cookies

If you leave a comment on our site you may opt-in to saving your name, email address and website in cookies. These are for your convenience so that you do not have to fill in your details again when you leave another comment. These cookies will last for one year.

Embedded content from other websites

Articles on this site may include embedded content (e.g. videos, images, articles, etc.). Embedded content from other websites behaves in the exact same way as if the visitor has visited the other website.

These websites may collect data about you, use cookies, embed additional third-party tracking, and monitor your interaction with that embedded content, including tracking your interaction with the embedded content if you have an account and are logged in to that website.

Please be aware that we have no control over the content and practices of these sites, and cannot accept responsibility or liability for their respective privacy policies.

Analytics

How long we retain your data

If you leave a comment, the comment and its metadata are retained indefinitely. This is so we can recognize and approve any follow-up comments automatically instead of holding them in a moderation queue.

For users that register on our website (if any), we also store the personal information they provide in their user profile. All users can see, edit, or delete their personal information at any time (except they cannot change their username). Website administrators can also see and edit that information.

What rights you have over your data

If you have an account on this site, or have left comments, you can request to receive an exported file of the personal data we hold about you, including any data you have provided to us. You can also request that we erase any personal data we hold about you. This does not include any data we are obliged to keep for administrative, legal, or security purposes.

Where we send your data

We don’t share any personally identifying information publicly or with third-parties, except when required to by law.

You are free to refuse our request for your personal information, with the understanding that we may be unable to provide you with some of your desired services.

Your continued use of our website will be regarded as acceptance of our practices around privacy and personal information. If you have any questions about how we handle user data and personal information, feel free to contact us.

This policy is effective as of 24 June 2018.

test checkout

Learning Hub

Privacy Policy

Your privacy is important to us. It is our policy to respect your privacy regarding any information we may collect from you across our website, https://profginabrown.com, and other sites we own and operate.

We only ask for personal information when we truly need it to provide a service to you. We collect it by fair and lawful means, with your knowledge and consent. We also let you know why we’re collecting it and how it will be used.

We don’t share any personally identifying information publicly or with third-parties, except when required to by law.

Our website may link to external sites that are not operated by us. Please be aware that we have no control over the content and practices of these sites, and cannot accept responsibility or liability for their respective privacy policies.

You are free to refuse our request for your personal information, with the understanding that we may be unable to provide you with some of your desired services.

This policy is effective as of 24 June 2018.

Dashboard

Please Sign-In to view this page

Student Registration

Oooh! Access Denied

You do not have access to this area of the application. Please refer to your system administrator.

Go to Home

Instructor Registration

Ooh! Access Denied

You do not have access to this area of the application. Please refer to your system administrator.

Go to Home

MERCURY 3

Improving the Prognostic Accuracy of Staging Rectal Cancer using Magnetic Resonance Imaging (MRI) – Detected Tumour Deposits and Vascular Invasion (mrTDV) instead of Tumour Nodal Metastasis (mrTNM)

IRAS Number: 348532
CPMS ID: 64773
ClinicalTrials.gov ID: NCT07054047

Trial Start Date: Apr-25
Recruitment End Date: Jul-26
Trial End date: Jul-31

A retrospective and prospective cohort study, MERCURY 3 aims to improve the prognostic accuracy of preoperative staging in patients diagnosed with rectal cancer.

This study seeks to prove that a different staging system of mrTDV which assesses tumour deposits (TDs) and tumour spread into veins (EMVI) will improve the quality of care of patients diagnosed with rectal cancer compared with the current practice of using TNM. We will do this by proving that the prognosis from using mrTDV is much more reliable and accurate than the current mrTNM.

We aim to prove that when radiologists look for Tumour Deposits or EMVI (mrTDV staging) on MRI scans, this improves the accuracy of how we document cancer behaviour when patients are first diagnosed and therefore oncologists and surgeons can use the information to plan the right kinds of treatment before surgery takes place.

REGISTRATION

← Back

Thank you for your response. ✨

If you do not receive confirmation of your registration and payment details after 2 working days, please email gina.brown@rmh.nhs.uk

If you wish to enquire about complimentary registration please email caroline.martin@rmh.nhs.uk

PRESERVE Patient Portal

“What is there to lose? As with many things in life, it is a matter of weighing up the risk, and with the type of monitoring regime in place – scans and endoscopy – the risk is low and there is still the fall-back option of having the second procedure.” R.M.

Many patients with early growths in the rectum (back passage) can have a safe removal of the growth through the back passage, and can avoid major abdominal surgery. However, the majority of patients are not offered this type of surgery because there has been difficulty in the past in being able to identify who can safely undergo this type of surgery.

We have found a new way of looking at MRI (magnetic resonance imaging) scans that can help us to improve how we find patients that could avoid major surgery and instead have the growth removed through the back passage. This procedure is known as “local excision”.

In the PRESERVE Trial we want to increase the number of operations that can be performed using local excision, by using this new MRI scan reporting system.

“It would help talking to other patients also going through this journey.” K.W.

Below are other websites that may be useful to you at different times during your journey.

Pelican Cancer Foundation www.pelicancancer.org/

Charity which drives innovation and development in bowel (colorectal), bladder, prostate and liver cancer treatment through research and education, and advancing precision surgery and treatment. So – our message is different. Our focus is on surgery, which provides the best outcomes and is often neglected.

Bowel Cancer UK bowelcanceruk.org.uk

Leading UK charity for bowel cancer patients, working to raise awareness of symptoms, promote early diagnosis and encourage open access to treatment choice for those affected by bowel cancer.

Healthtalk.org healthtalk.org/peoples-experiences/cancer/colorectal-cancer/topics

Healthtalk.org comes from a unique partnership between a charity called DIPEx and The Health Experiences Research Group or ‘HERG’ at The University of Oxford’s Nuffield Department of Primary Healthcare Sciences. It provides free, reliable information about health issues, by sharing people’s real-life experiences.

Macmillan Cancer Support macmillan.org.uk/information-and-support/bowel-cancer

UK charity providing practical advice and support in all areas of life for people diagnosed with cancer including financial and emotional support.

PRESERVE

Pre-therapeutic MRI assessment of Early-Stage Rectal Cancer and Significant Rectal Polyps to avoid major resectional surgery

IRAS Number: 256736
CPMS ID: 41403
ClinicalTrials.gov ID: NCT04103372

Trial Start Date: Feb-24
Recruitment End Date: Dec-26
Trial End date: Apr-32

When patients are diagnosed with rectal (bowel) cancer radiology doctors read MRI scans to describe how deeply the cancer invades into the bowel wall – this is the ‘stage’ of the cancer. Almost 1/3 of screen detected rectal cancers are limited to the bowel wall without nodal spread yet many patients with Early Rectal Cancer (ERC) are currently over-treated, as demonstrated below.

Current management of ERC – based on a recent study (Detering et al (2020))^[1], data from the UK national NBOCA audit and local audit data from a typical NHS hospital

The main cause of over-treatment of ERC is over-staging of the MRI, which occurs due to lack of certainty or experience by radiology doctors. There is a tendency to over-estimate the stage of the cancer to err on the side of caution, but this leads to over-treatment. Patients then undergo major surgery or unnecessary radiotherapy when local excision surgery to preserve the patient’s rectum, and quality of life, would have been possible. As a consequence, only 10% of patients with ERC are currently staged accurately and offered local excision.

We have created and tested a more accurate staging system for ERC – the PRESERVE MRI Specialised Reporting Tool (mrSRT). Our pilot work (Balyasnikova et al) showed this improved identification of ERC suitable for local excision, with 89% accuracy.

We will train radiologists in the PRESERVE mrSRT to prevent over-staging. By providing patients with accurate information about their cancer and stage this empowers patients to make informed decisions about their treatment, and in particular in avoiding major surgery. The mrSRT will lead to reduced health inequality, as it will reduce variability in reports and allow all patients access to high quality staging reports.

Balyasnikova, S., Read, J., Wotherspoon, A., Rasheed, S., Tekkis, P., Tait, D., . . . Brown, G. (2017). Diagnostic accuracy of high-resolution MRI as a method to predict potentially safe endoscopic and surgical planes in patients with early rectal cancer. BMJ OPEN GASTROENTEROLOGY, 4(1), 9 pages. doi:10.1136/bmjgast-2017-000151

Pan London Early Rectal Cancer Meeting 2018

PRESERVE Patient Portal

PRESERVE Early Rectal Cancer Meeting 2024

Pan London Early Rectal Cancer Meeting

Ensuring patient choice and access to the PRESERVE Trial

1st November 2018, Royal Society of Medicine, London

“I made some choices; the outcomes are good. I remain positive.” K.W.

Multidisciplinary teams attended a day of lectures, expert panel discussions and break out sessions to establish a consistent pathway for early rectal cancer, increasing identification of patients suitable for local excision, and developing the management pathway for early rectal cancer as outlined in the Colorectal Cancer Guidelines (previously published Cancer Alliances in London) and commissioned NHS England service specification.

Mr Ken Webster, our Patient Representative on the PRESERVE trial, agreed to take part in a panel with Dr Diana Tait and Prof Gina Brown to discuss his experiences of being diagnosed with rectal cancer, the choices he was given at his consultation and how his life has changed through the treatment he has received. We were also able to receive comments from other patient representatives prior to the meeting that we were able to present to the audience.

“I am very pleased and relieved that the TEMs procedure was successful, thanks to the skill of the consultant and operating team. I’m happy that the TEMs procedure could be used rather than the more invasive procedure.” R.M.

Presentation slides

How to set up and maintain the SPECC early rectal cancer MDT Mr Francesco Di Fabio

Identification and pathway of lesions for organ-preserving local excision approach Dr Kevin Monahan

Endoscopic submucosal dissection of rectal lesions Dr Paul O’Toole

TEM TAMIS patient selection Mr Chris Cunningham

TEM full-thickness techniques and TAMIS Mr Tony Miles

Improving precision of staging SPECC and early rectal lesions, and road-mapping for local excision Prof Gina Brown

PRESERVE Project launch Miss Annabel Shaw

Adjuvant therapy – selective post-excision therapy in moderate and high risk cancers to enable organ preservation Dr Diana Tait

Assessment and onward guidance following local excision. Defining high, moderate and low risk cancers Prof Marco Novelli

Early Rectal Cancer Translational research opportunities Dr Katharina von Loga

Endoscopic submucosal dissection of rectal lesions Mr Amyn Haji

How to set up and access support for PRESERVE in your hospital Mr Graham Branagan

Delegates attended from: Amsterdam UMC; Basingstoke North Hampshire Hospital; Brighton and Sussex University Hospital NHS Trust; Chelsea & Westminster NHS Foundation Trust; Churchill Hospital, Oxford; Croydon University Hospital; East and North Herts NHS Trust; East Suffolk and North Essex Foundation Trust; Epsom and St Helier University Hospitals; Hampshire Hospitals NHS Trust; Imperial College Healthcare NHS Trust; King’s College Hospital NHS Foundation Trust; London North West University Healthcare NHS Trust; Oxford University Hospitals; RM Partners (London Cancer Alliance); Royal Liverpool and Broadgreen University Hospitals; Royal Marsden NHS Foundation Trust; Salisbury NHS Foundation Trust; St George’s University Hospitals NHS Foundation Trust; St Mark’s Hospital; University College London Hospitals NHS Foundation Trust; University Hospitals of North Midlands

Reporting Proformas

The following proformas are in Word format

Please feel free to copy and paste into your RIS systems as proforma voice recognition shortcuts

Baseline MRI Rectal Staging Assessment

Beyond TME compartment staging

Colon Staging Baseline

Early rectal cancer or Significant polyp MRI assessment

Post Treatment Assessment of Rectal Cancer

Cart

Your cart is currently empty!

Checkout

My account

Login

Shop

Please join us for our 6th International Colorectal Symposium

Our objectives for the day are:

To give updates on all our trials
For trial delivery teams to discuss and get support in delivering our trials
For funders and investigators to meet and network
For invited patients and public to join in a session to discuss how to improve our engagement and inclusivity
To help research supervisors and research fellows with career development

Hope to see you there!

“It was the most exciting and thought-provoking meeting that I have ever attended”

“I do enjoy these meetings which are extremely informative and what I find most stimulating is the focus on future research. You are to be congratulated for organising these meetings and I am delighted to take part”

“I really enjoyed the discussions and the whole format of the day”

“Thanks for allowing me to attend the Symposium on rectal cancer, which was really outstanding in underscoring the many needs we have in this field. I enjoyed it very much”

“Sounds fantastic”

“Inspiring talks and very interesting discussions, great meeting”

“Thank you for such an outstanding meeting, one of the best – a very inspiring day!“

“I know how good these meetings are”

“Thank you for the symposium yesterday. I returned on the train last night with renewed enthusiasm and a desire to try and improve our service.“

“I am sure that it will be as entertaining and thought provoking as ever”

Beyond TME Origins

Investigating the origins of pelvic recurrence in colorectal cancer

IRAS Number: 136843
CPMS ID: 17065
ClinicalTrials.gov ID: NCT02292641

Trial Start Date: Sept-14
Recruitment End Date: Dec-26
Trial End date: Dec-31

We are trying to find out where, why and how patients get recurrent bowel cancer in their pelvis. We also want to find out which treatments can help. In this study we are introducing a new format for reporting MRIs which provides more detailed information about the recurrence which will improve management of your recurrence and therefore outcome. We will also compare this new structured report with the original scans of the original tumour which will help us understand how this recurrence happened. We hope that by understanding how these recurrences occur we can prevent them from occurring in the future.

A prospective and retrospective cohort study, Beyond TME Origins aims to improve surgical and treatment planning using an imaging assessment proforma of advanced and recurrent colorectal cancers. This involves the implementation of imaging assessment proformas describing anatomic pelvic compartments and aetiology of disease recurrence for treatment planning.

All patients with recurrent colorectal cancer in the pelvis are eligible. The original primary tumour staging scans and resected surgical specimen needs to be available. Patients’ recurrence will be staged using our proposed MRI classification. We will be assessing the original primary staging scans and histopathology to learn about risk factors for recurrence. We will record treatment for the recurrence, and patients will be followed up for three years.

The Beyond TME trial is open to new sites.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

← Back

Thank you for your response. ✨

TRIGGER

Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker to Stratify Management of Good and Poor Responders to Radiotherapy: A Rectal Cancer Multicentre Randomised Control Trial to avoid surgery with ‘watch and wait’ or intensify treatment according to mrTRG

Non-CTIMP trial protocol

IRAS Number: 156408
CPMS ID: 20576
ClinicalTrials.gov ID: NCT02704520

Trial Start Date: Mar-16
Recruitment End Date: Dec-26
Trial End date: Dec-36

After patients receive preoperative treatment for locally advanced rectal cancer, MRI scans are performed. Currently the MRI scan reading is not used to make decisions about further treatment plans. This trial will test if viewing the MRI scans in a different way, that we have developed and will teach to other radiologist, it is possible to assess how the tumour has responded to treatment. This technique is called the ‘mrTRG’ (MRI Tumour Regression Grade). We plan to offer watch and wait according to the mrTRG.

The only phase III clinical trial in the UK offering watch and wait, the TRIGGER trial aims to validate mrTRG as an imaging biomarker for the stratified management of patients with locally advanced rectal cancer. The ‘good responders’ (mrTRG1&2) often have no evidence of tumour and it may be possible to avoid surgery in this group and so maintaining QoL while not impacting survival rates. The ‘poor responders’ (mrTRG3-5) are at high risk of poor oncological outcomes and this knowledge is useful in planning ongoing treatment and surveillance. TRIGGER is now a non-cTIMP trial as the protocol does not specify chemotherapy or IMP treatments. Decisions about the use of chemotherapy will be based upon local MDT discussions as is normal practice and national policy and the trial CRFs will capture these decisions and whether more treatment is given to patients or not. TRIGGER does not mandate or recommend the use of any treatments: specifically it does not suggest the use of investigational medicinal products. If any centre wishes to use IMPs this would be in the context of separate trial protocols and would not preclude entry into TRIGGER.

Open to patients undergoing any pre-operative treatment for locally advanced rectal cancer, TRIGGER is the only phase III clinical trial in the UK offering watch and wait. All patients will have post treatment MRI scans routinely performed, no change from the MERCURY trials high resolution MRI protocol is required. Patients will be randomised to either the control arm for management according to national guidelines – conventional MDT, clinical assessment post-treatment planning using the baseline MRI. Patients in the interventional arm will have their post treatment MRI scans read by a radiologist trained and supported to reliably report the mrTRG grade and have their management directed accordingly – ‘Good response’ (mrTRG 1&2) – watch and wait (avoidance of surgery) offered. ‘Poor response’ (mrTRG 3-5) – local colorectal MDT is informed and uses information to discuss and agree next steps in treatment and surveillance. Patients are followed up for five years with QoL questionnaires completed at registration, 3 and 5 years.

The TRIGGER trial is open to new sites.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

← Back

Thank you for your response. ✨

SOPRANO

Study Of PRoliferation and Apoptosis in rectal caNcer as predictive and prognostic biOmarkers: a histopathology and imaging analysis (SOPRANO)

Treatment for rectal cancer involves a course of chemo and radiotherapy (CRT) followed by major abdominal surgery to remove the tumour. After MRI scans performed after CRT have shown that up to 40% of patients will have an extremely good response to treatment with no visible residual tumour. Clinicians question the value of major surgery and its associated complications for a cancer that has effectively ‘disappeared’. However, by not operating on patients, are we leaving viable cancer cells behind and putting patients at risk of recurrence? What is needed is a marker that will predict and measure a patient’s response to CRT at a cellular level, in order to confirm and validate the MRI findings.

The DNA in a cancer cell is damaged. A healthy cell would ‘self-destruct’, a process known as apoptosis. However, cancer cells evade apoptosis and replicate in an uncontrolled manner leading to growth of the tumour. CRT works by causing cancer cells to undergo apoptosis. We believe we can use apoptosis as a marker for the cell ‘death’ seen after CRT. The SOPRANO trial will use a special stain for ‘dead cells’ and count the number of cells with DNA damage. This will give an apoptotic index and should directly equate to a patients response to CRT. This together with the MRI findings would enable us to give patients a more accurate picture of how their tumour is likely to behave in the future and whether or not they would require an operation or further drug treatment. SOPRANO will also measure proliferation, which is a marker of continued cancer growth and will add to the biological basis for our treatment decisions.

The SOPRANO trial is now closed to recruitment.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

← Back

Thank you for your response. ✨

MINSTREL

Mri IN STaging REctal polyp planes (MINSTREL)

Website: http://minstrelstudy.co.uk/

Patients undergoing TEMS can benefit from reduced mortality, impotence, hospi-tal stay and avoiding a stoma that may be associated with pelvic surgery. Currently few of the patients eligible for TEMS are offered it for a variety of reasons that include uncertainties about the risk of leaving residual tumour and the increased risk of subsequent recurrence of cancer within the pelvis. Currently guidelines state there is no role for imaging in assessing the malignant polyp.

We hope to prospectively test our hypothesis that an MRI scan can accurately gauge depth of tumour spread in an unselected group of benign and malignant tumours measuring be-tween 20mm and 50mm in size. We will identify eligible patients awaiting surgery / poly-pectomy and if they consent to our pilot study they will undergo an MRI to assess their tumour which assesses safety at all levels of the rectal wall. Should MRI prove sensitive and specific then we hope to change national guidelines to mandate MRI to standardise assessment and thereby increase the appropriate use of TEMS in the UK.

The MINSTREL trial is open to new sites.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

← Back

Thank you for your response. ✨

6 vs 12

Optimum timing for surgery after pre-operative radiotherapy

In rectal cancer, radiotherapy is frequently given prior to surgery to enable complete removal and reduce recurrence. Uncertainty remains regarding the timing of surgery and a delay to 12-14 weeks has been hypothesised as advantageous.

The 6vs12 trial is a multicentre randomised clinical trial. Individuals diagnosed with rectal cancer of T3 stage and above will be identified at colorectal MDT and offered randomisation between surgery at 6-8 or 12-14 weeks following completion of radiotherapy. PET/CT, pelvic MRI and final histopathology will be used to determine the response to radiotherapy. The degree of down-staging and tumour regression at 6-8 versus 12-14 weeks will then be compared.

The 6 vs 12 trial is now closed to recruitment.

You can view and download a pdf copy of the protocol here.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

← Back

Thank you for your response. ✨

IMPRESS

Improving radical treatment through MRI evaluation of pelvic sigmoid cancers

IRAS Number: 137312
CPMS ID: 17006
ClinicalTrials.gov ID: NCT02222844

Trial Start Date: Aug-14
Recruitment End Date: Dec-26
Trial End date: Dec-29

We want to test whether the information from an MRI gives more accurate information than a CT scan about tumours in the sigmoid colon. This trial will also enable us to find out whether having an MRI scan prior to surgery could improve the treatment choices offered to patients.

A randomised phase II multicentre trial, IMPRESS will determine whether the use of MRI imaging in staging sigmoid cancers results in a change to the treatment plan by identifying more high risk tumours compared to those patients who were staged using CT imaging. The proposed intervention will be additional radiological and pathological assessment and the reporting of supplementary diagnostic information which would not otherwise have been available. This may affect treatment according to local MDT protocols and also affect the provision of prognostic information to patients in subsequent discussions.

Patients with suspected or proven sigmoid colon adenocarcinoma, eligible for curative treatment whose MRI can be reviewed prior to surgery and has no decision regarding radical treatment are eligible. Patient are randomised to the control arm which the standard care of preoperative CT imaging and subsequent discussion by the Multidisciplinary Team or the interventional arm which has the additional use of MRI imaging and subsequent discussion by the Multidisciplinary Team. Patients are followed up at 1 and 3 years together with QoL questionnaires.

The IMPRESS trial is open to new sites.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

← Back

Thank you for your response. ✨

Working together to improve rectal preservation rates in patients with early rectal cancer

All members of the colorectal MDT and research portfolio teams are welcome, including clinicians, nurses, coordinators, managers and any healthcare professional who attends

The Royal Society of Medicine
1 Wimpole Street
London W1G 0AE

PROGRAMME

EXPERT FACULTY

PR ESERVE TRIAL

Registration is now closed

Please email c.martin1@imperial.ac.uk for further information

Deferral of Surgery

The Timing and Deferral of Rectal Surgery Following a Continued Complete Response to Pre-operative Chemoradiotherapy

There has been growing interest in selecting, pre-operatively, those rectal cancer patients who are likely to achieve pathological complete response (pCR) following pre-operative chemoradiotherapy. This is of particular importance for patients with low rectal cancers who would otherwise require an Abdomino-perineal resection and a permanent stoma.

In those patients with an optimal response on MRI, a ‘scar’ replaces the site of disease, rep-resented by a focal area of low-signal intensity on T2-weighted MR. The precise cellular composition of such an area of low signal intensity cannot be known, and a single MRI scan cannot diagnose complete response. However, if surgery is deferred, then the ‘scar’ may be monitored with serial imaging, clinical examination and CEA to exclude any change. By adopting this approach, the time interval to maximal tumour debulking can be established and identification of true ‘complete responders’ may be made (sustained radiological and clinical complete response for at least 1 year after CRT).

The Deferral of Surgery Trial is a single-centre interventional study. Patients follow a schedule of imaging, endoscopy and clinic appointments over a 10 year period. If a tumour re-grows, patients are quickly referred for surgery. The aim of the study is to show that the percentage of patients who can successfully avoid surgery is at least 10%.

The Deferral of Surgery trial is now closed to recruitment.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

← Back

Thank you for your response. ✨

SERENADE

Screening for synchronous metastases in colorectal cancer with DW-MRI

IRAS Number: 135981
CPMS ID: 17059
ClinicalTrials.gov ID: NCT02246634

Trial Start Date: Aug-14
Recruitment End Date: Dec-26
Trial End date: Aug-31

It has recently been suggested that limited MRI of the liver can identify most spread to the liver. We therefore wish to test whether an additional quick MRI scan of the liver at regular intervals for patients with bowel cancer can identify spread to the liver better than the current standard of only a CT scan.

A phase II multicentre, interventional study, SERENADE will determine if additional staging at diagnosis with liver DW-MRI will diagnose more synchronous metastases than CT alone in patients with high risk colorectal cancer. Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local policy.

Eligible patients with high risk colorectal malignancy (T3/4, spread greater than 5mm, EMVI positive) will have additional surveillance of breath hold T1, T2 and DW-MRIs (no IV contrast) post surgery six monthly for three years.

Findings of liver MRIs as reported by radiology PI will be shared with their local MDT who make decisions as appropriate, including the management of any identified liver metastases, according to local protocol.

The SERENADE trial is open to new sites.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

← Back

Thank you for your response. ✨

Sigmoid WISE

The Sigmoid WISE study

We wish to investigate the ‘waist’ in the distal sigmoid mesentery and define the sigmoid. Identification of the level in the distal sigmoid colon and where ‘waisting’ occurs will enable us to stage tumours at this level as high-risk on pre-operative imaging. Definition of the sigmoid colon by anatomical landmarks using MRI will differentiate upper rectal and sigmoid colon tumours to improve management.

Hypothesis

There is a narrowing of the upper rectum and the sigmoid mesentery and that this may increase the risk of an incomplete resection.
MRI imaging can be used to define the upper extent of the rectum and the beginning of the sigmoid.

Aims

To determine whether there is a level at which the ‘waisting’ occurs in the recto-sigmoid mesentery and the variability present within the population
To compare anatomical landmarks of the rectosigmoid junction on MRI and histopathology
To determine differences in measurements on MRI with CT and histopathology of:
- the distance of the rectum from the anal verge
- the length of the “rectosigmoid junction”
- the dimensions of the mesorectum and mesocolon.

The WISE trial is open for recruitment

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

← Back

Thank you for your response. ✨

ctDNA

Circulating tumour DNA (ctDNA) in patients with colorectal cancer and the relationship to imaging features of extramural venous invasion

IRAS Number: 136894
CPMS ID: 19730
ClinicalTrials.gov ID: NCT02579278

Trial Start Date: Oct-15
Recruitment End Date: Dec-26
Trial End date: Nov-29

Extramural venous invasion (EMVI) is the spread of microscopic tumour cells into the veins around the tumour. When people develop cancer, microscopic cells and fragments of DNA can be released into the blood circulation. This could be one way that cancers recur in the future. We hope to identify differences within the blood in certain types of rectal cancer which will help us improve future treatments.

A multicentre observational study, ctDNA aims to provide the evidence base for metatstatic disease being caused by vascular methods of spread by determining if there is a link between EMVI status and ctDNA.

This study does not involve randomization or treatment. Eligible patients have colorectal adenocarcinoma with no metastases eligible for curative surgery. A pre operative staging scan must have been completed within 6 weeks prior to surgery. Two x 20ml blood samples will be taken from each patient, one prior to and one during or within 24hrs after surgery. Patients are annually followed up to 3 years.

The ctDNA trial is open to new sites.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

← Back

Thank you for your response. ✨

Professor Gina Brown MBBS MD MRCP FRCR FASCRS (Hon)

Professor of Gastrointestinal Cancer Imaging

Imperial College London

email: gina.brown@imperial.ac.uk

http://scholar.google.com/citations?user=BwinzQIAAAAJ&hl=en

My research in colorectal cancer staging has set the national and global benchmarks for imaging assessment of colon and rectal cancer patients before and during treatment . These improved staging methods have reduced local and distant failure in high risk patients whilst avoiding overtreatment of low risk patients and has resulted MRI based strategies being incorporated into several guidelines such as peer review measures, UK NICE and guidelines.

I graduated from King’s College Hospital School of Medicine, London in 1988, and my research career began at the University of Wales, Cardiff in 1997 with my investigating and establishing optimal MRI techniques for staging and assessment of primary rectal cancer.

I defined other markers of tumour aggression venous invasion and peritoneal ulceration not previously assessed by imaging techniques, and showed that MRI has significant clinical and cost benefits over traditional methods of staging and published the importance of multidisciplinary team discussion of imaging in preventing recurrence. These have now become a global standard of care for the primary evaluation of rectal cancers.

In 2009 I identified factors predicting positive-margins in low rectal cancer as I had previously showed patients undergoing abdominoperineal excision have worse outcomes from higher involved margin rates. I developed a staging model describing the anatomical and surgical planes for low rectal cancer for planning radical surgery and the type of chemoradiotherapy given. I initiated investigation of imaging prognostic factors in colon and rectal tumours with outcome data. I initiated and led a large prospective multicentre observational study (MERCURY); subsequent analysis of the data showed that MRI scans could be used to predict those patients with a high risk of positive margins in low rectal cancer and this also correlated with survival outcomes.

I developed and published a staging model describing the anatomical and surgical planes of low rectal cancer so that future outcomes for high risk patients could be improved through imaging derived selective planning of radical surgery and chemoradiotherapy.

I also developed an MRI compartmental classification scheme to improve radiology reporting in patients with very advanced pelvic cancer to reduce incomplete resection rates validated in the Beyond TME trial. Analysis of final results (2019) show high local cure rates for very advanced cancers.

In 2015 I developed an MRI methodology to assess tumour regression and predict patients that can be safely operated on after chemoradiotherapy. This was validated as a prognostic and predictive biomarker and will enable the preoperative stratification of patients to further intensive therapy or less radical treatment (e.g. watch and wait). 2021 results show that over 40% of UK patients treated for advanced bowel cancer randomised in the trial successfully avoided surgery. This has never previously been achieved by an imaging intervention.

I have built on my research in rectal cancer to develop and validate a CT prognostic staging system for high risk colon cancer showing the potential benefits of preoperatively treating high risk colon tumours and I have published on the advantages of preoperatively treating high risk colon tumours. I have recently validated a new staging system that is superior to TNM for assessing colon cancers using CT based T substaging tumours using measured extramural spread, tumour deposits and EMVI.

In 2019, I published an MRI method to identify the junction of the sigmoid mesocolon (ie, the “sigmoid take-off”) was tested and shown to help classify tumours into rectal, rectosigmoid, or sigmoid based on location relative to the take-off. A global Delphi expert panel supported this approach which is now being implemented in several countries to improve consistency.

In 2020 I advanced methods to identify previously unseen and poorly understood pathways of spread of colorectal cancer in vivo. I characterised tumour deposits and venous invasion on imaging (40% prevalence) and showed greater significance for cancer outcomes than lymph nodes.

I have successfully supervised 21 PhD and MD students and I have trained and mentored Specialist GI Cancer Radiologists in Barcelona. I have held meet the professor and workshops at ASCO,ASCRS,(2009, 2011, 2016), Melbourne (biannually 2008 to date), Laparoscopic surgery course. Strasbourg, National Danish TME and low rectal courses 2009-2011, FICARE 2009, 2011 Brazil, , European Congress of Radiology (2019, 2020), GI ESMO (2022, 2023).

Formal radiology training is embedded in many of the trials for which I am CI and I run dedicated teaching workshops for radiologists, surgeons and oncologists which are internationally attended. I have collaborated with international research groups at Ontario Cancer Care (linking in with MERCURY study, the RCR CASPAR initiative, and the Beyond TME collaboration). Sao Paolo, McGill Universities Hospitals and the MD Anderson. I have been invited as the Radiology Faculty Expert for colorectal cancer quality improvement initiatives in Denmark and Norway, training several hundred multidisciplinary clinicians in colorectal cancer management Through my links with the Pelican Cancer Foundation, I have been the radiology faculty lead in many international outreach educational courses including the Dutch colorectal group, and MDT group, Israel..

I have contributed to the NHS workforce development through teaching on large scale national training initiatives funded through the Department of Health: the National TME Multidisciplinary Team Development Programme (2003-6), teaching the role of high resolution MRI in staging to 180 MDT teams; I was Faculty lead in Radiology for the Low Rectal Cancer National Development programme (National Cancer Action Team), (2010/2013) for improving outcomes in patients with low rectal cancers (147 colorectal MDTs and 151 NHS trusts); Invited faculty lead in Imaging of Significant Polyps and Early Colorectal Cancer national SPECC programme and the IMPACT initiative for improving MDT decision making and cancer care. I am Imaging Lead for the National Cancer Intelligence Network to improve cancer reporting standards and datasets in NHS cancer care and I was Imaging Lead for the first UK-wide NHS initiatives to improve Bowel Cancer care: National TME MDT development I was an invited expert and co-author of pan-European consensus guidelines for optimal treatment of colorectal cancer, EURECCA colorectal (2014). Author of imaging standards for the latest European (ESMO) 2017 Oncology guidelines for the management of rectal cancer. Invited to expert panel for ASCO Neoadjuvant Therapy Guideline for Rectal Cancer 2023. I am the Imaging Representative on ACPGBI Council – embedding imaging into surgical quality improvement initiatives.

I have mentored junior colleagues and supported my contemporaries throughout my career as it is important to me not just to promote academic success but support anyone who feels unable to discuss their career path with senior colleagues. I give space and time to reassure colleagues that there is no single route or pathway to success, as I share my own journey of embedding research into my daily working practice. I actively invite opinion in my teaching, collaborations and daily working as I am acutely aware that, in particular, there is a cultural/female reticence to speak up. I have found that colleagues quite often just don’t know where to start and I am always happy to be a sounding board to help them develop in confidence and purpose. I am open about the challenges I have faced in my career as it is important for me to develop mutually supportive working communities, and to help others do the same.

MARVEL

Molecular pAthologic and MRI investigation of the prognostic and predictive importance of extramural VEnous invasion in rectaL Cancer

Very little is known about the long-term outcomes and response to CRT on MRI detected ex-tramural venous invasion (mrEMVI). Although mrEMVI is accepted as a marker of poor prog-nosis, whether it has a predictive value and should be specifically treated is not known.

Molecular and genetic profiling provides us with an opportunity to understand the underlying mechanisms which govern clinical behaviour in rectal cancer. It offers the ability to compare the molecular profiles of different subtypes of rectal cancer such as mrEMVI-positive and – negative tumours and whether any changes are observed following CRT. This can then be cor-related with clinical behaviour over the medium and long-term with regards to local recur-rence, distant metastases and overall survival.

MARVEL is a multicentre, observational study that collects data and tissue from patients with rectal adenocarcinoma who have had pre-operative chemoradiotherapy.

Primary endpoint: Difference in Relapse Free Survival (RFS) between EMVI positive and negative (on pre-treatment MRI) patients, measured from date of surgery.

The MARVEL trial is now closed to recruitment.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

← Back

Thank you for your response. ✨

MERCURY II

Low Rectal Cancer Study

With better staging and documentation of the tumours and radial/ circumferential margins (pathologically) preoperatively, a reduction in margin positivity rates can be achieved.

The Low Rectal Cancer Study (short title MERCURY II) is a multicentre observational study of patients with low rectal adenocarcinoma.

The main hypothesis is that accurate MRI staging pre-operatively will allow the correct patients to receive neo-adjuvant chemoradiotherapy (CRT), and also pre-warn the surgeons if the resection margins appear threatened so that the operation can be modified to take this into account, leading to a reduction in margin (CRM) positivity .

The cohort was divided into two analysis populations, phase I, which includes all patients recruited up to and including December 1^st 2011, and phase II, including all patients recruited subsequently to March 3rd 2013. Recruitment is now closed and follow-up is due to continue until March 2018.

The MERCURY II trial is now closed to recruitment.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

← Back

Thank you for your response. ✨

COMET

Concordance in MRI and Pathology Diagnosis of Extranodal Tumour Deposits

IRAS Number: 217627
CPMS ID: 35640
ClinicalTrials.gov ID: NCT03303547

Trial Start Date: Oct-17
Recruitment End Date: Dec-26
Trial End date: Dec-31

We are studying how imaging can be used to improve the accuracy of how a tumour is classified. This will give us a better understanding of how different tumours behave. We will perform the standard imaging tests and patients will have same operation. The only difference is how the bowel specimen is processed in the laboratory. We will take photographs of the bowel after it has been cut into slices and match this up with the scans.

A prospective interventional multi-centre study, COMET aims to prove the accuracy of imaging diagnosis of extranodal tumour deposits (TD) and their adverse effect on prognosis of colorectal cancers. The proposed intervention will be additional radiological and pathological assessment and the reporting of supplementary diagnostic information which would not otherwise have been available. This may affect treatment according to local MDT protocols and also affect the provision of prognostic information to patients in subsequent discussions.

Any patient with a suspected primary adenocarcinoma of the colon, sigmoid or rectum undergoing surgery are eligible. The date of surgery must be known prior to registration. This trial aims to determine if image mapping techniques can improve the concordance between imaging and pathology detection of tumour deposits. Lymph nodes and tumour deposits will be identified on pre-operative scans and mapped by radiologists then shared with pathologists prior to processing the resected specimen. Patients will be managed at their local hospital with standard follow-up. Patients will be followed up for 5 years.

The COMET trial is open for recruitment.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.

← Back

Thank you for your response. ✨

Rectal MRI virtual handson workshops

Research driven evidence based understanding of colorectal cancer for the benefit of patients

Audience: radiologists, surgeons and oncologists

The workshop will provide you with essential knowledge for MDT working and MRI assessment in different clinical scenarios with details revision of anatomy and interpretation criteria with hands on workstation practice for assessing rectal cancer cases and pelvic anatomy and how this is applied to treatment planning to optimise patient care through your MDTs.

Registration fee: £695

18 CPD points

DATES

Monday 12th, Tuesday 13th January 2026 SOLD OUT

Monday 11th, Tuesday 12th May 2026 SOLD OUT

Monday 14th, Tuesday 15th September 2026 SOLD OUT

Monday 23rd, Tuesday 24th November 2026

How is the course run?

We have replicated the real world handson workshop online so there are the same periods of self study, lectures, worked examples, discussions and self assessments as before. The only difference is that we rely more on you to be fully engaged.

We expect you to complete staging of all cases and assessments that we set throughout the course and to submit your answers via our voting app. By doing this Gina can understand how best to tailor her teaching to you. Although she can’t physically stand behind you, through screen sharing she can answer individual questions but in a way that benefits the group. Everyone will be given the opportunity to present case examples in real time so that Gina can pass on practical tips as to how stage in a methodical way when presenting at an MDT. Because of this approach we do not record the lectures – this is a truly handson course!

We aim for you to leave the course not with a list of correct answers to a specific set of cases, but with a set of practical tools that you can use in your MDTs and rectal cancer reporting.

We are able to organise and run a bespoke course for your institution or network – please click here for more information.

What do I need to attend?

Hardware

External mouse – All programmes will run on a standard computer but you will need a mouse with a scroll button to use the PACS software successfully. A touchpad will not suffice.

Webcam – we are trying to recreate a ‘real world’ workshop as much as possible and so it is important that during lectures and discussions following self study periods that Gina and your fellow delegates are able see you

Software

You will receive links to all of the software in advance of the course so you can make sure you are able to fully participate.

Zoom – what else? Please practice saying ‘Can you see my screen? ‘ and ‘You’re on mute’…

Cimar – Virtual PACS for course teaching and self study. You will be asked to share your screen so please launch this on the same computer as Zoom.

Slido – online voting app used to record assessment answers – we recommend you use this on your phone or another computer so that you don’t have to keep swapping windows

Click below to register for the next course on 23rd and 24th November 2026

DRIVEN

A multicentre retrospective analysis of pre-operative prognostic biomarkers in resected right compared with left colon cancer and the influence of operative approach on survival

IRAS Number: 287131
CPMS ID:
ClinicalTrials.gov ID:

Trial Start Date: Nov-20
Recruitment End Date: Dec-26
Trial End date: Dec-27

A retrospective, non-interventional tissue study using archival materials collected through a patient’s routine care, DRIVEN aims to validate the ctTDV staging system as a prognostic biomarker for use in all colon cancers.

The ctTDV system evaluates the depth of tumour invasion, presence or absence of tumour deposits and/or extramural venous invasion. If DRIVEN is successful in validating ctTDV, this could be used to stratify treatment for patients with right colon cancer with the aim of improving patient outcomes and reducing the disparity in overall survival between those with right sided and left sided colon cancer. Further retrospective tissue analysis on colonoscopic biopsy samples with assessment of other known prognostic biomarkers including the immune score and tumour budding will establish whether or not these too have a role, alone, or in combination with the ctTDV staging system in personalising treatment for patient’s with right colon cancer.

Patients who underwent surgery at hospitals who perform CME surgery and hospitals who perform Non-CME surgery with curative intent colon cancer between January 2010 and December 2019 are eligible. As DRIVEN is a retrospective study, there are no time dependent schedules for CRF completion or tissue submission.

EVIDENCE

EMVI as a determinant of metastasis in colorectal cancer

IRAS Number: 288231
CPMS ID: 55248
ClinicalTrials.gov ID:

Trial Start Date: Oct-20
Recruitment End Date: Dec-26
Trial End date: Dec-28

A retrospective ,non-interventional tissue study using archival materials collected through a patient’s routine care, EVIDENCE aims to demonstrate that distant metastases in colorectal cancer are related to EMVI and tumour deposits, not lymph nodes.

We will test whether the vascular route of spread (as evidenced through EMVI and tumour deposits) is more important than lymph nodes in the development of metastatic disease. We will compare the subclonal origins of primary colorectal cancers, EMVI, tumour deposits, lymph nodes and distant metastases by reconstructing phylogenetic trees. A proof for a vascular route of spread rather than lymph nodes would lead to a paradigm shift in future decision making at national and international level.

Patients who have undergone a primary resection of their colon or rectum as well as a resection of a distant metastases are eligible. As EVIDENCE is a retrospective study, there are no time dependent schedules for CRF completion or tissue submission.

Bespoke Rectal MRI virtual handson workshops

We are able to tailor our online rectal MRI workshops for MDT team members (surgeons, radiation oncologists and radiologists) who wish to integrate MRI assessment into their decision-making processes to optimise treatment options for their patients.

We can offer both one and two day formats for the course.

Please submit the form below to start the discussion.

← Back

Thank you for your response. ✨

Thank you for contacting us we will reply within 2 working days.

Tickets Checkout

Purchase Tickets

Checkout Error!

Something went wrong!

Oops, no tickets!

Please browse events and add tickets to check out.

Order Completed

Whoops!

No order information is available because no purchase was made.

Second Opinion Referral

We are able to provide a second opinion on colon and rectal cancer.

This includes assessment of the primary tumour and arranging multi-specialty review of your case.

Please fill in the form below with your details.

← Back

Thank you for your response. ✨

Thank you for contact us we will reply within 24hrs.

About us

Professor Gina Brown MBBS, MD, MRCP, FRCR, FASCRS (Hon)

Professor of GI Radiology and Consultant Radiologist

Imperial College London

email: gina.brown@imperial.ac.uk

Miss Caroline Martin, GI Imaging Research and Education Programmes Manager

email: c.martin1@imperial.ac.uk

Mrs Syvella Ellis, Trial Manager,

email: syvella.ellis@imperial.ac.uk

Contact

Please use the form below to contact us.

You are able to register on our courses by going to the ‘Our Courses’ option in the menu, selecting the course you wish to register for and filling in the form on that page.

You are able to ask for information about a specific clinical trial we are running by going to the ‘Clinical Trials’ option in the menu, finding the trial you wish to know more about and filling out the form on that page.

If you have not received a reply within 3 working days please email gina.brown@imperial.ac.uk

← Back

Thank you for your response. ✨

Blog

This is the page where users will find your site’s blog